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Abstract 
Diseases of the hypothalamic-pituitary-adrenal (HPA) axis are commonly encountered in dogs and include 
deficiency or excess of cortisol hormone, termed hypoadrenocorticism and hyperadrenocorticism respectively. 
Assessment of the HPA axis requires special endocrine assays including the adrenocorticotropic hormone 
(ACTH) stimulation test, which uses exogenous ACTH to stimulate cortisol production. The most commonly used 
preparation of ACTH in Australia is Synacthen® (tetracosactrin, Mallinckrodt™ Pharmaceuticals, Staines-upon-
Thames, Surrey, UK), which has been intermittently unacquirable. A compounded preparation of synthetic ACTH 
(tetracosactide, Bova Aus, Caringbah, NSW, Australia) has been available for several years in Australia and 
offers veterinarians an alternative ACTH for use in testing. It is unknown whether the compounded ACTH has an 
equivalent effect at increasing blood cortisol concentrations during ACTH stimulation testing compared to 
Synacthen. Determining its effect in healthy dogs would be the first step towards legitimate use of Bova ACTH in 
the diagnosis and treatment monitoring of HPA disease in dogs by Australian veterinarians. It is also unknown 
whether subject variables may affect the HPA axis and ultimately the blood cortisol concentration.  
Objectives 
1. To establish reference intervals (RI) for an on-site biochemical analyser, as a component of enrolling
healthy dogs, prior to its use in the main study.
2. To establish the equivalence of the serum cortisol response to compounded Bova ACTH by comparing
serum cortisol concentrations 1 hour after the administration of 5 µg/kg of compounded Bova ACTH
versus Synacthen in healthy dogs.
3. To explore the effect of subject factors on the variation of cortisol concentrations in healthy dogs.
Methods 
RI were established for the biochemical analyser COBAS INTEGRA® 400 plus (Roche, Basel, Switzerland) through 
a combination of transferring RI from another analyser and generating RI de novo for non-transferable values. The 
latter used data obtained from assaying stored serum samples from a previous study of healthy dogs.   
The second objective was achieved through an experimental study of 20 healthy dogs owned by staff and students 
at a veterinary teaching hospital. A haemogram, biochemistry profile and urinalysis were performed in 20 dogs to 
confirm their health status prior to enrolment into the ACTH response equivalence study. Ten dogs received 
Synacthen first and Bova ACTH 24 hours later. Ten dogs received Bova ACTH first and Synacthen 24 hours later. 
ACTH stimulation testing was performed by collecting blood prior to (t=0), and 1 hour after (t=1) injection of ACTH 
intravenously. Serum was separated and later assayed for cortisol concentration.  
Predetermined limits of equivalence were set for the 95% confidence interval (CI) of the ratio of cortisol 
concentration after stimulation with Bova versus Synacthen to be within 0.8-1.25. Bland Altman analysis provided 
visual representation of agreement and calculation of mean bias and limits of agreement (equivalence). Passing-
Bablok regression analysis was used to examine any systematic and proportional bias between cortisol 
concentrations after Bova ACTH versus Synacthen stimulation.  
The final objective was achieved by using the data from the equivalence study to explore subject factors that may 
explain variance in cortisol concentration after Synacthen stimulation. Variables entered into the multiple linear 
regression model included neuter status, sex, basal cortisol concentration, age, body condition score, sodium: 
potassium ratio, haematocrit, neutrophil count, eosinophil count, lymphocyte count, and presence or absence of a 
stress leukogram. Based on results of this analysis, univariate comparison of serum cortisol concentration for the 
single-most explanatory variable was performed using a t-test. 
Results 
Seventeen biochemistry analytes had RI established which were then used in screening candidate dogs for ACTH 
stimulation. Despite normal results from screening haematology, biochemistry and urinalysis, 2 dogs had ACTH 
stimulation results that were markedly outside of laboratory RI. One dog had very low cortisol concentrations and 
1 dog had very high cortisol concentrations. Results from these 2 dogs were removed from further statistical 
analysis. Of the remaining 18 dogs, the 95% CI of the ratio of cortisol concentration after Bova ACTH/Synacthen 
was 0.98-1.04. The Bland Altman analysis calculated a bias of 1.01 (95% CI 0.97-1.05) and 95% limits of 
agreement of 0.87 (95% CI 0.81-0.93) and 1.17 (95% CI 1.09-1.25). Passing-Bablok regression analysis identified 
no consistent bias. These results confirm that Bova ACTH produces equivalent cortisol concentrations after ACTH 
stimulation compared to the reference standard Synacthen in healthy dogs.  
The best single variable explaining the variance in cortisol concentration was neuter status, explaining 48% of the 
variance in t=1 cortisol concentration. This improved to 55% with the inclusion of basal (t=0) cortisol 
concentration. Finally, the addition of lymphocyte count improved the explanation to 57%. Entire dogs (3 females 
and 1 male) had significantly lower mean cortisol concentration compared to neutered dogs (5 females and 9 
males). 
Conclusion and clinical relevance 
Bova ACTH results in equivalent cortisol concentrations after ACTH stimulation compared to the reference 
standard Synacthen in healthy dogs. Bova ACTH is a reasonable alternative for Australian veterinarians when 
planning ACTH stimulation testing and faced with a shortage of Synacthen, however further research into dogs 
with HPA dysfunction is needed to fully confirm equivalency of the Bova ACTH preparation.  
Further research is also needed to determine the role subject characteristics have on the HPA axis, specifically the 
variation in blood cortisol concentrations. If significant variability is associated with factors such as neuter status, 
then different RI may be appropriate for dogs that are neutered versus entire.  
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Compounded drugs allow increased flexibility in sourcing drugs as well as reducing cost. Compounded drugs are 
not tested in the same manner as commercial drugs prior to sale, and it is the responsibility of the prescribing 
clinician to verify the equivalency of a compounded drug. Verifying a compounded drug can be generally 
performed either by measuring the drug concentration in vitro or in vivo, or by testing its outcome in vivo. In the 
first instance, the drug concentration can be measured directly from the preparation prior to administration, or 
from blood/tissue after administration. In the second instance, outcomes that could be measured include the 
eradication of an infection, the alleviation of pain or the hormonal changes in response to a drug. The latter type 
of testing can be performed in healthy, or sometimes sick, animals and outcomes are compared to confirm 
equivalence between a compounded product and a reference standard. Equivalent outcomes would infer that the 
drugs are comparable without directly measuring the drug concentration in vitro. In veterinary medicine, there is 
the added complication that a compounded drug needs to be separately verified in each different species. More 
research into this area is needed and this thesis focuses on one compounded drug and its use in dogs.  
A compounded preparation of synthetic adrenocorticotropic hormone (ACTH) has been available in Australia for 
several years. Tetracosactide (hereby referred to as “Bova ACTH”) is produced by Bova Aus (Caringbah, NSW, 
Australia). The commercially available synthetic ACTH used in Australia, tetracosactrin (Synacthen), is produced 
by Mallinckrodt Pharmaceuticals (Staines-upon-Thames, Surrey, UK), and is hereby referred to as “Synacthen”. 
Synacthen has been unacquirable in Australia for prolonged periods in the past and during these times an 
alternative source of synthetic ACTH is needed by veterinary practitioners to provide comprehensive care to their 
patients.  
The work covered in this thesis was conducted in several phases. Firstly, validation of an on-site biochemistry 
analyser was performed with the purpose of using the analyser to accurately identify healthy dogs for inclusion in 
the equivalence study. 
The second phase of the study comprised an equivalence study comparing compounded Bova ACTH to the 
reference Synacthen in healthy dogs. The ACTH stimulation test was chosen as the method for verifying 
equivalence, as the test represents the main intended use for synthetic ACTH in veterinary medicine. The ACTH 
stimulation test involves measurement of serum cortisol concentration before and 1 hour after the intravenous 
(IV) administration of ACTH. Results from this test can determine abnormally increased secretion of cortisol 
(hyperadrenocorticism) or decreased secretion of cortisol (hypoadrenocorticism) from the adrenal glands.(1) 
The third phase concerned analysis of the data from the equivalence study to explore the effect of subject 
variables on serum cortisol concentration after ACTH stimulation. Variables examined included neuter status, 





2. Literature review 
2.1 The hypothalamic-pituitary-adrenal axis 
The hypothalamic-pituitary-adrenal (HPA) axis regulates the production of multiple hormones including 
glucocorticoids, mineralocorticoids and sex hormones. The axis is comprised of three major endocrine glands: 
the hypothalamus, the pituitary and the bilateral adrenal glands (Figure 1). 
The hypothalamus produces corticotrophin-releasing hormone (CRH), which stimulates adrenocorticotropic 
hormone (ACTH) release from the corticotropic cells located in the anterior pituitary.  
ACTH is a 39-amino acid polypeptide (Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-
Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-glu-Ala-Phe-Pro-Leu-Glu-Phe), which is 
synthesised via the cleavage of pro-opiomelanocortin (Figure 2).(2) 
Secretion of ACTH from the pituitary gland stimulates cortisol production in the adrenal glands. The adrenal 
glands are located cranial to the kidneys and are composed of an outer cortex and medullary core. The cortex is 
further divided into the zona glomerulosa, zona fasciculata and zona reticularis (Figure 3).(3) 
Cortisol is a glucocorticoid hormone produced by the zona fasciculata and zona reticularis within the adrenal 
glands. Cortisol is responsible for a myriad of body functions and has roles in glucose, protein and fat 
metabolism, and regulation of the immune system.(4)  
The zona glomerulosa layer of the adrenal gland produces aldosterone (a mineralocorticoid), a component of the 
renin-angiotensin-aldosterone system.(3) Aldosterone production increases in response to an increase in serum 
potassium concentration and/or angiotensin II stimulation. ACTH has a minor role in aldosterone secretion and 
Figure 1 Canine hypothalamic-pituitary-adrenal axis and the negative feedback loops (blue arrows) that regulate 
hormone production. CRH: corticotrophin-releasing hormone; ACTH: adrenocorticotropic hormone. Adapted from 
Feldman 2015.(3) 
hypophysectomised dogs with no circulating ACTH do not develop mineralocorticoid deficiency.(3) The effects of 
aldosterone include increased sodium retention and potassium excretion by the kidneys.  
 
 
The HPA axis has negative feedback loops by which an increasing cortisol concentration decreases production of 
CRH and ACTH.(4) In healthy dogs, these negative feedback loops regulate blood cortisol concentrations within 
a physiologic range. Loss of regulation can occur from different disease pathomechanisms, with the end result 
being either excessively low cortisol (hypoadrenocorticism) or excessively high cortisol concentrations 
(hyperadrenocorticism). 
  
Figure 2 Precursor pro-opiomelanocortin is synthesised by corticotrophs in the anterior pituitary before it is cleaved 
into smaller active peptides, including adrenocorticotropic hormone. Adapted from Feldman 2015.(3) 
Figure 3 Diagrammatic representation of an adrenal gland and the different layers of the adrenal cortex. Adapted 
from Hall 2016.(4) 
2.2 Diseases of the hypothalamic-pituitary-adrenal axis 
Disease caused by deficiency (hypoadrenocorticism) or excess (hyperadrenocorticism/hypercortisolism) of 
glucocorticoids is recognised in dogs and many other species, including people.(1, 5, 6) Dysregulation of cortisol 
production can result from primary pituitary disease, primary adrenal disease or exogenous drug administration. 
Table 1 Clinical signs adapted from ACVIM Hyperadrenocorticism Consensus Statement 2012.(7) 
2.2.1 Hyperadrenocorticism 
The prevalence of hyperadrenocorticism in dogs was estimated at 0.28% (95% CI 0.25-0.31) in an 
epidemiological study conducted in the United Kingdom.(8) A similar prevalence study is not available for 
Australia; however, the disease is diagnosed frequently in veterinary practice.(9) 
Naturally occurring hyperadrenocorticism can occur via two main pathologic mechanisms. The most common 
form is pituitary-dependent hyperadrenocorticism, where there is overproduction of endogenous ACTH due to 
benign or rarely malignant neoplasia of the pituitary gland.(1) The excessive ACTH production leads to 
overstimulation of the adrenal glands and resultant hypercortisolism. Hyperadrenocorticism can also develop due 
to benign or malignant adrenal neoplasia (adrenal-dependent hyperadrenocorticism), affecting one or both 
adrenal glands. A functional adrenal neoplasm produces excessive cortisol independent of ACTH 
concentrations.(1) The resulting clinical signs of hypercortisolism are the same regardless of the pituitary or 
adrenal origin of disease. Clinical signs can include increased thirst, urination, appetite and weight gain (Table 1). 
Treatment of hyperadrenocorticism is aimed at reducing cortisol concentrations and includes medical and 
surgical options. Table 2 lists two frequently used drugs for the medical management of hyperadrenocorticism in 
dogs. Trilostane (4, 5-epoxy-17-hydroxy-3-oxoandrostane-2-carbonitrile) is a synthetic steroid analogue and 
competitively inhibits the enzyme 3-β-hydroxysteroid dehydrogenase (Figure 4). Trilostane decreases the 
availability of the enzyme for cortisol synthesis and to a lesser extent, aldosterone synthesis.(10, 11) Mitotane 
(9o,p’DDD or 2,2-bis [2-chlorophenyl-4-chlorophenyl]-1,1-dichloroethane) is metabolised in adrenocortical tissue 
to a reactive acyl chloride intermediate. This metabolite is toxic to the surrounding adrenal cortical cells (namely 
Clinical signs of hyperadrenocorticism 
Frequent Less frequent Infrequent 
Polydipsia Lethargy Thromboembolism 
Polyuria Hyperpigmentation Ligament rupture 
Polyphagia Comedones Facial nerve palsy 
Panting Thin skin Pseudomyotonia 
Abdominal distention Poor hair regrowth Testicular atrophy 
Endocrine alopecia Urinary incontinence Persistent anoestrous 
Hepatomegaly Insulin-resistant diabetes mellitus  
Muscle weakness   
Systemic hypertension   
the zona fasciculata, zona reticularis and to a lesser extent zona glomerulosa) and in this manner reduces blood 
cortisol production.(1, 3) 
The dose of trilostane or mitotane to achieve the desired treatment outcome is unpredictable in dogs and each 
dog may require a different dose to reduce blood cortisol concentrations and control the clinical signs of 
hyperadrenocorticism. One prospective clinical trial in 30 dogs reported that trilostane doses of 5.3-50 mg/kg/day 
were necessary to attain adequate control of hyperadrenocorticism.(12)  
Although the treatment aim is to reduce circulating cortisol to within a physiologic range, there is the risk that the 
medications can lead to excessive suppression of cortisol (iatrogenic hypoadrenocorticism). A retrospective study 
of 159 dogs receiving trilostane estimated the cumulative incidence of iatrogenic hypoadrenocorticism was 15% 
over a 2-year period.(13) Iatrogenic hypoadrenocorticism can be life threatening and prevention during treatment 
of hyperadrenocorticism requires regular ACTH stimulation testing and subsequent dose adjustment. Thus, 
access to ACTH stimulation testing is integral to gold-standard management of hyperadrenocorticism in dogs. 
 
Table 2 Two frequently used drugs for the medical treatment for hyperadrenocorticism in dogs 












Figure 4 Enzymatic action of 3β-hydroxysteroid dehydrogenase is essential for synthesis of glucocorticoids 
(corticosterone and cortisol) and mineralocorticoid (aldosterone, which requires corticosterone as a substrate). 
Trilostane competitively inhibits 3β-hydroxysteroid dehydrogenase and thus decreases the enzymatic conversion 
as demarcated by the green line. Diagram modified from Feldman 2015.(3) 
2.2.2 Iatrogenic hyperadrenocorticism 
Exogenous administration of glucocorticoids (such as prednisolone or dexamethasone) can lead to clinical signs 
of hyperadrenocorticism. Diagnosis relies on a compatible history, and iatrogenic hyperadrenocorticism can be 
confirmed with ACTH stimulation testing. Prolonged used of exogenous glucocorticoids leads to adrenal cortical 
atrophy and resultant decreased production of cortisol after ACTH stimulation.(14, 15) The ACTH stimulation test 
can be used to distinguish iatrogenic hyperadrenocorticism from spontaneous hyperadrenocorticism in dogs 
receiving exogenous glucocorticoids. Once a diagnosis of iatrogenic hyperadrenocorticism is confirmed, 
treatment consists of slowly withdrawing the administered glucocorticoid.  
2.2.3 Hypoadrenocorticism 
Hypoadrenocorticism describes a deficiency of glucocorticoids with or without accompanying deficiency of 
mineralocorticoids. It usually is a result of direct damage to the adrenal glands via immune-mediated destruction, 
infarction, infiltration by neoplastic cells or infection.(1, 16) Rarely, hypoadrenocorticism can occur secondary to 
inadequate ACTH production from the pituitary gland.(1) Hypoadrenocorticism can also be iatrogenic in origin, 
after medical or surgical treatment for hyperadrenocorticism. 
 
Table 3 Frequency of clinical signs of hypoadrenocorticism. Modified from Klein 2010.(16) 
The clinical signs of hypoadrenocorticism occur due to insufficient glucocorticoid secretion with or without a 
change in mineralocorticoid (i.e. aldosterone) secretion. Insufficiency of glucocorticoids can lead to vomiting, 
diarrhoea, dehydration, hypotension, and hypothermia (Table 3). Dogs that lack glucocorticoids also commonly 
lack a stress leukogram (i.e. neutrophilia, lymphopenia, eosinopenia) despite being clinically ill.(17, 18) 
Insufficient mineralocorticoid secretion leads to electrolyte imbalances, including hyponatraemia and 
hyperkalaemia. The latter, if severe, can result in life-threatening bradycardia.(1) A sodium to potassium ratio 
(Na:K) of less than 25 is common, though not pathognomonic for hypoadrenocorticism-related mineralocorticoid 
deficiency. A ratio of less than 15, however, is strongly suggestive of hypoadrenocorticism.(19) 
Hypoadrenocorticism can be a fatal disease and a definitive diagnosis facilitates appropriate treatment (i.e. 
hormone replacement with a glucocorticoid or mineralocorticoid or both). The only definitive diagnostic assay for 
Clinical signs of dogs with hypoadrenocorticism (%) 
Poor appetite/anorexia 88-95 Thin body condition 82 
Lethargy/depression 85-95 Dehydration 42 
Vomiting/regurgitation 68-75 Shock/collapse 24-29 
Weakness 51-75 Hypothermia 15-34 
Weight loss 40-50 Bradycardia 22-25 
Diarrhoea 35 Weak femoral pulses 22 
Polyuria/polydipsia 17-25 Melena/haematochezia 17 
Shaking/shivering/tremors 17-27 Collapse 10 
Prior response to nonspecific fluid or 
corticosteroid therapy 
35 Painful abdomen 8 
Hair loss 5   
hypoadrenocorticism is the ACTH stimulation test, with diagnosis based on inadequate increase in blood cortisol 
concentrations after ACTH administration.  
Treatment for hypoadrenocorticism includes correction of clinical signs and metabolic derangements (including 
dehydration and electrolyte imbalances) and supplementation with exogenous glucocorticoids and if necessary 
mineralocorticoids.(20) Options for glucocorticoid replacement include prednisolone or cortisone acetate.(20, 21) 
Options for mineralocorticoid supplementation include desoxycorticosterone pivalate (DOCP, Percorten-V®; 
Elanco Animal Health, Greenfield, Indiana, USA) or fludrocortisone acetate (Florinef®; Monarch, Bristol-Myers-
Squib, Princeton, New Jersey, USA).(20) 
2.3 Testing of the adrenal axis 
There are numerous options for investigating HPA axis function in dogs, with ACTH stimulation testing being the 
most relevant to the current study. As stated earlier, the ACTH stimulation test is the gold-standard for diagnosis 
of hypoadrenocorticism, however, no gold-standard exists for diagnosing hyperadrenocorticism. Parallel testing 
with two or more different assays may be necessary to increase diagnostic accuracy.  
2.3.1 Basal blood cortisol measurement 
A single blood cortisol measurement is unreliable for the diagnosis of both hypoadrenocorticism and 
hyperadrenocorticism due to the normal daily fluctuations of blood cortisol concentration.(7) In dogs, episodic 
variation in plasma cortisol concentration does not follow a circadian or any other definable pattern.(22) Hence a 
single measurement of very low or very high blood cortisol concentration is insufficient to indicate HPA function.  
Despite the lack of utility of basal blood cortisol concentration for confirming a diagnosis of hypoadrenocorticism, 
it may have value as a screening test to exclude hypoadrenocorticism. A retrospective case series by Peterson 
and others (1996), reported that basal cortisol concentrations in 225 dogs diagnosed with hypoadrenocorticism  
ranged from 3 to 41 nmol/L (RI 25-125).(23) Two retrospective studies found that a basal cortisol concentration 
below 2 µg/dL (55.2 nmol/L) was 100% sensitive for the diagnosis of hypoadrenocorticism in dogs.(24, 25) The 
same studies calculated the test specificity to be 63.3 and 78.8%.(24, 25) A later study used receiver operating 
characteristic curve analysis to assess the utility of basal cortisol concentration at different cut-off values in 522 
dogs.(26) When basal cortisol concentration below 55 nmol/L was used to diagnose hypoadrenocorticism, the 
calculated sensitivity was 99.4% and specificity was 67%. The very high sensitivities reported in three different 
studies support the use of basal cortisol measurement as a screening test to exclude canine 
hypoadrenocorticism, with a suggested cut-off of 55 nmol/L. However, the poor specificities have led all authors 
to still recommend an ACTH stimulation test to confirm a diagnosis of hypoadrenocorticism.(3, 24, 25)  
Measurement of a basal cortisol concentration is not useful for the diagnosis of hyperadrenocorticism as healthy 
dogs can have transient periods where blood cortisol concentrations are elevated.(22) Cortisol is also naturally 
increased in response to stress; thus, a single high measurement could reflect stress associated with 
handling/venipuncture or a nonadrenal illness, rather than reflecting adrenal dysfunction.(27) For these reasons, 
basal cortisol concentrations have no role in diagnosing or screening for hyperadrenocorticism. 
2.3.2 Dexamethasone suppression test 
The dexamethasone suppression test assesses the sensitivity of the HPA axis to negative feedback from an 
exogenous glucocorticoid. The test protocol involves measurement of blood cortisol concentration prior to 
dexamethasone administration and then at four (t=4) and eight (t=8) hours after dexamethasone 
administration.(7) 
In healthy dogs, dexamethasone causes suppression of pituitary ACTH secretion and consequently, decreased 
cortisol production from the adrenal glands. This is reflected in decreased blood cortisol concentrations at t=4 
and t=8. In dogs with hyperadrenocorticism, cortisol concentrations remain high and there is inadequate 
suppression of cortisol production after dexamethasone administration. 
Dexamethasone is utilised as the exogenous glucocorticoid in suppression testing as it is not detected on 
standard laboratory cortisol assays. An in vitro study examined the cross reactivity of eight different steroids 
using the Cobas® 601 cortisol competitive immunoassay (Roche, Basel, Switzerland).(28) The study found 
dexamethasone had a cross reactivity of 0.9-3.2% on the cortisol assay, which was interpreted as clinically 
insignificant and was significantly lower than the cross reactivity of prednisolone (42.6-71.1%). Negligible cross 
reactivity to dexamethasone was also reported with the ADVIA Centaur® competitive immunoassay for cortisol 
(Bayer Diagnostics, Leverkusen, Germany),(29) Immulite® 1000 (Siemens, München, Germany),(30) and 
Immulite® 2000 (Siemens, München, Germany).(31)  
The sensitivity and specificity of dexamethasone suppression testing for diagnosis of hyperadrenocorticism varies 
according to different studies. Reported sensitivities are, in increasing order, 0.85 (95% CI 0.76-0.91),(32) 
0.92,(33) 0.96,(34) and 1.0.(27, 35, 36) The reported specificities are 0.44,(27) 0.7,(34) and 0.73 (95% CI 0.56-
0.86).(32) Contributing factors to differences in sensitivity and specificity include different cut-off cortisol 
concentrations used for diagnosis and different subject populations used in each study (e.g. pituitary versus 
adrenal-dependent hyperadrenocorticism). Another confounding factor when interpreting sensitivity or specificity 
is the lack of a gold standard test for comparison. For example, one study examining 100 dogs assigned dogs 
(n=20) to a “healthy” control group based on a normal clinical history and physical examination.(27) The same 
study assigned dogs to a “non-adrenal disease” group based on lack of suspicion of hyperadrenocorticism and a 
confirmed diagnosis of another disease (including pancreatitis, cholangiohepatitis and diabetes mellitus). A 
weakness of this approach was not excluding the possibility that these dogs had hyperadrenocorticism in addition 
to their primary disease.  
The cut-off cortisol concentration for diagnosis of hyperadrenocorticism varies between laboratories, with no 
universally recognised value. Previously reported cut-offs used for diagnosis of hyperadrenocorticism after a low-
dose dexamethasone suppression test include cortisol concentrations above 20 nmol/L at t=4 and t=8 (assay not 
identified),(37) above 30 nmol/L at t=4 and t=8 (using Elecsys/Cobas Cortisol, Roche, Basel, Switzerland),(38) 
and above 40 nmol/L at t=8 (using a radioimmunoassay).(32) In comparison, a sentinel veterinary internal 
medicine textbook defines inadequate suppression as a cortisol concentration above 38.6 nmol/L at t=4 and 
t=8.(1) 
The differences in cut-off concentrations likely reflects different assays and laboratories, which can produce 
varying cortisol concentrations when measuring the same sample.(7) For this reason, it is recommended that 
each laboratory establish their own reference intervals (RI), factoring in assay variability, as well as potential 
differences in the local canine population.(7) Local validation by laboratories to establish their own RI is also 
recommended in human medicine.(39, 40) The different cut-offs set by the individual laboratories also affect the 
sensitivity and specificity of the test. With all other testing and subject characteristics being equal, a higher cut-off 
cortisol concentration decreases the sensitivity and increases the specificity for diagnosis of 
hyperadrenocorticism. 
A study by Bennaim and others (2018) examined 123 dogs suspected to have hyperadrenocorticism, with 59 
dogs assigned a final diagnosis of hyperadrenocorticism and 64 dogs with a final diagnosis of non-adrenal 
illness.(41) The positive and negative predictive values of the low-dose dexamethasone suppression test in 
differentiating dogs with hyperadrenocorticism versus non-adrenal illness were examined. The criteria for 
appropriate suppression was a cortisol concentration below 27.59 nmol/L at t=4 and t=8. Responses other than 
complete suppression at both times were further defined under the study criteria (Table 4). For example, a lack of 
suppression was defined by a cortisol concentration above 27.59 nmol/L and more than 50% of basal 
concentration at t=4 and t=8; a partial suppression was defined by a cortisol concentration above 27.59 nmol/L 
but less than 50% of basal concentration at t=4 and t=8; an escape pattern was when the cortisol concentration 
was below 27.59 nmol/L at t=4 but above 27.59 nmol/L at t=8; and an inverse pattern was when cortisol 
measured above 27.59 nmol/L at t=4 but below 27.59 nmol/L at t=8. 
Table 4 outlines the calculated positive and negative predictive values associated with the study’s predefined 
cortisol patterns, with positive predictive values ranging from 40-93.9%. A complete suppression pattern had a 
negative predictive value of 95.6% for confirming the absence of hyperadrenocorticism.(41)  
 
Table 4 Patterns of complete suppression, partial suppression, escape pattern and inverse pattern after low-dose 
dexamethasone suppression and use in diagnostic interpretation in a population of 123 dogs suspected to have 
hyperadrenocorticism. Prevalence of hyperadrenocorticism was 48%. Modified from Bennaim, 2017.(41) CI, 
confidence interval  
Two variants of the dexamethasone suppression test are used clinically; low-dose (0.01 mg/kg IV) and high-dose  
(0.1 mg/kg IV) versions, which as the names suggest, differ in the dose of dexamethasone administered.(3) Use 
of the different doses can sometimes help to discriminate between pituitary-dependent versus adrenal-dependent 
hyperadrenocorticism. Partial suppression after high-dose dexamethasone supports a diagnosis of pituitary-
dependent hyperadrenocorticism, however the test does not have perfect discriminating ability.(3, 42) Both 
versions of the dexamethasone suppression test can deliver equivocal results for diagnosing 
hyperadrenocorticism. Thus, other tests for adrenal function are often required.  
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t=4 <27.59 nmol/L 
35.7 (10.6-60.8) - 
t=8 >27.59 nmol/L 
Inverse pattern 
t=4 >27.59 nmol/L 
40 (0-82.9) - 
t=8 <27.59 nmol/L 
2.3.3 ACTH stimulation test 
The ACTH stimulation test is another method of assessing the HPA axis and involves maximal stimulation of 
cortisol production from the adrenal glands. The maximum cortisol concentration is not affected by daily 
fluctuations and approximates the adrenal reserve. A low or high blood cortisol concentration after ACTH 
stimulation can diagnose hypoadrenocorticism or hyperadrenocorticism respectively.(43-46) The test protocol 
consists of first measuring blood cortisol concentration, followed by exogenous ACTH administration, and lastly 
measuring blood cortisol after a set interval (most commonly 1 hour after ACTH administration).(7, 47)  
ACTH stimulation is the only definitive test for hypoadrenocorticism in the dog, with typical blood cortisol 
concentrations below 55 nmol/L before and after ACTH stimulation.(23) Both iatrogenic and spontaneous 
hypoadrenocorticism can be life-threatening and early diagnosis is essential. For this reason, it is important to 
have not only a reliable source of ACTH but also a preparation with predictable properties and actions. 
The diagnosis of hyperadrenocorticism is less straightforward. An elevated cortisol concentration after ACTH 
administration is highly supportive of hyperadrenocorticism but non-adrenal illness can produce similar results 
and confound the diagnosis.(48) The sensitivity and specificity of ACTH stimulation for the diagnosis of 
hyperadrenocorticism varies according to different authors. Reported sensitivities are 0.80,(27) 0.84 (95% CI 
0.725-0.917),(49) and 0.95(34); and specificities are 0.59 (95% CI 0.454-0.707),(49) 0.86,(27) and 0.91.(34) The 
variable sensitivities and specificities likely reflect multiple factors within each study and make direct comparison 
difficult. Some variables that have already been discussed in association with the dexamethasone suppression 
test (2.3.2) include differing cortisol concentration cut-offs for diagnosis of hyperadrenocorticism, varying cortisol 
assays, and different populations of dogs examined in each study. For example, populations of dogs with non-
adrenal illness are very heterogeneous and will have different impacts on calculated ACTH stimulation specificity. 
Another variable affecting sensitivity and specificity calculations is the type of ACTH preparation used, with 
different studies using different ACTH manufacturers (e.g. ACTH gel, Anthony Corp, California USA,(34) 
Cortrosyn, Amphastar Pharmaceuticals, California USA,(49) and synthetic cosyntropin).(27) Any potential 
differences in potency may affect the cortisol concentration after administration. Differences in ACTH 
preparations are further reviewed in 2.4.1. 
The ACTH stimulation test can also be used to diagnose iatrogenic hyperadrenocorticism, which is caused by 
exogenous glucocorticoid administration. Glucocorticoids lead to classic clinical signs of hyperadrenocorticism as 
well as adrenocortical suppression and atrophy via negative feedback on the HPA axis. Glucocorticoids must be 
withdrawn prior to testing and iatrogenic hyperadrenocorticism can be diagnosed with a low t=1 cortisol 
concentration.  
ACTH stimulation testing is also used to confirm adequate response to medical treatment of 
hyperadrenocorticism.(12) The extent of HPA axis suppression by trilostane or mitotane can be deduced by the 
cortisol concentration after ACTH stimulation, which should be within a target range. ACTH stimulation testing 
also detects iatrogenic hypoadrenocorticism, which requires dose reduction or discontinuation of trilostane or 
mitotane.(1, 12, 50)  
Mitotane treatment involves an induction period of daily dosing, followed by a maintenance period of smaller 
intermittent doses.(50) As each dog often requires a different induction dose, ACTH stimulation testing is used 
together with clinical response to determine the duration of induction and when to transition to a maintenance 
dose.(51) Repeated ACTH stimulation testing is also recommended every 3-6 months for dogs receiving 
maintenance mitotane treatment, as their dosage requirements can change over time.(1) Long-term trilostane 
treatment also requires ACTH stimulation testing every 3 months, as trilostane dosage requirements can likewise 
change over time.(12)  
2.4 ACTH stimulation test protocol 
2.4.1 Adrenocorticotropic hormone 
Exogenous ACTH is used for ACTH stimulation and this molecule can be purified from human or animal pituitary 
glands or be manufactured, with synthetic ACTH providing the bulk of supply in the current market. The ACTH 
molecule is strongly conserved across mammalian species, with identical ACTH sequences between people and 
whales, bovines and ovines, and rats and mice.(2) Comparison of the sequencing between bovine and porcine 
ACTH found differences only in the amino acid residues at position 31 and position 33.(2) The POMC 
(proopiomelanocortin) gene, recently sequenced in Labrador retrievers, indicates only one amino acid difference 
in the ACTH peptide compared to people.(52) There have also been numerous experimental and clinical studies 
over decades that have successfully used porcine ACTH or synthetic ACTH (designed for human use) to 
stimulate the canine HPA.(53, 54) 
2.4.1.1 Natural adrenocorticotropic hormone 
Porcine ACTH was the first preparation used in dogs prior to the availability of synthetic ACTH.(55) Past studies 
in dogs have used Highly Purified Acthar® Gel (Mallincokrodt, Staines-upon-Thames, Surrey, UK)(47, 56) and 
Adrenomone (Armour-Baldwin Laboratories, Omaha, Nebraska, USA).(55) Acthar® Gel has been the centre of a 
recent controversy in light of an increase in price in the USA by 85,000% to $34,000 a vial.(57) At this cost, the 
preparation is not economically viable for veterinary use. Purified Corticotrophin (Virbac Australia, Milperra, NSW, 
Australia) is another natural ACTH preparation which has been studied in Australian dogs, but is no longer 
manufactured.(47)  
As natural ACTH is purified from the pituitary glands of animals, there is concern for contamination and 
standardisation of the final product.(58) A case series by Forssman and others (1963) described 13 individuals 
who became sensitised to ACTH of human and porcine origin with hypersensitivity IV reactions evidenced by 
urticaria and fever, and positive intracutaneous testing.(59) A contaminant animal protein or the ACTH 
polypeptide were the two main suspected causes of hypersensitivity but neither possibility could be confirmed. 
2.4.1.2 Synthetic adrenocorticotropic hormone 
Commercially manufactured synthetic ACTH is a replication of the first 24 amino acid sequence of natural ACTH, 
which has an identical biologic effect to the full 39 amino acid sequence.(60) The synthetic preparation of the first 
24 amino acids (Figure ) are synonymously known as tetracosactide,(61) tetracosactrin,(62) cosyntropin,(63) or 
tetracosactide acetate.(64)  
By removing the 15 amino acid non-biologically active portion from the naturally occurring 39 amino acid ACTH, 
manufacturers claim that the antigenic activity of the synthetic preparation is reduced, compared to ACTH derived 
from animals.(65) This theory is reasonable as any decrease in epitopes should trigger fewer hypersensitivity 
reactions after administration. In addition, the synthetic preparation removes the risk of contamination from other 
animal proteins, a risk which cannot be eliminated from the natural ACTH preparation, despite continued 
improvements in manufacturing protocols for purification of animal pituitary glands. 
The difference in sensitisation between natural and synthetic ACTH is described in several case reports in 
people, in which individuals who developed hypersensitivity to porcine ACTH could still safely receive synthetic 
ACTH as part of treatment for chronic immune-mediated conditions (such as asthma or multiple sclerosis).(66-
68) The time frame for development of sensitisation in predisposed people ranged from months to years after 
receiving multiple doses of the animal origin ACTH. One woman received intermittent ACTH for 15 years before 
developing clinical signs consistent with a type I hypersensitivity reaction against porcine ACTH; however, she 
did not develop signs after the administration of the synthetic ACTH.(66) This difference was confirmed by 
positive intradermal testing and positive serum IgE antibody ELISA testing against the porcine but not the 
synthetic ACTH.(66)  
Unfortunately, hypersensitivity to synthetic ACTH is also possible and was reported in a man who was sensitised 
to porcine, human and synthetic ACTH containing the first 24 amino acid sequence.(69) The hypersensitivity 
manifested as urticaria and anaphylaxis, and confirmatory testing showed positive intracutaneous and Prausnitz-
Küstner’s reactions against ACTH of animal or synthetic origin.(69) Tests for anti-ACTH antibody were negative.  
There are no published reports of hypersensitivity in dogs related to either porcine or synthetic ACTH. One 
experimental study looked at the feasibility of vaccinating healthy dogs against the ACTH polypeptide to develop 
an alternative treatment for pituitary-dependent hyperadrenocorticism.(70) The study documented the use of a 
recombinant peptide consisting of three copies of ACTH fused to a T-helper cell epitope (produced by 
Escherichia coli). Anti-ACTH antibodies were detected shortly after the first injection and subsequent booster 
injections, but concentrations rapidly declined by 15 weeks after the initial injection.(70) At this time, there was no 
Figure 5 Chemical structure of tetracosactrin, also known as tetracosactide.(63)  
change in basal cortisol concentrations or response to ACTH stimulation, which suggested that vaccination 
resulted in only a transient immune reaction against endogenous ACTH.(70)  
In Australia, tetracosactrin (Synacthen, Mallinckrodt Pharmaceuticals, Surrey, UK) is the main ACTH preparation 
used for testing. It is licensed for ACTH stimulation testing in people (Australian Registration Number 11058) and 
is also widely used in veterinary hospitals. Unfortunately, the availability of Synacthen is sometimes limited and 
an alternative preparation is required in veterinary medicine. Synacthen is not licenced by the USA Food and 
Drug Administration (FDA) and its use and efficacy has been mainly examined by European and Australian 
researchers.(47, 71) 
A similar synthetic preparation, cosyntropin (Cortrosyn®, Amphastar Pharmaceuticals, Rancho Cucamonga, 
California, USA), is not available in Australia. Literature originating from the USA regarding synthetic ACTH refers 
largely to Cortrosyn and rarely to Synacthen.(33, 56, 72, 73) The increasing cost of Cortrosyn has also been a 
subject of concern.(74)  
Cortrosyn and Synacthen contain the same 24 amino acid sequence (Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-
Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro), with the main difference being the excipients 
(mannitol in Cortrosyn versus acetic acid, sodium acetate, and sodium chloride in Synacthen).(60, 65) Both 
preparations report 10 µg to be equivalent to 1 international unit of natural ACTH. No studies have compared 
cortisol concentrations after stimulation with Synacthen versus Cortrosyn in dogs.  
2.4.1.3 Synthetic adrenocorticotropic hormone: depot preparation 
Synacthen Depot (available in Australia) contains ACTH adsorbed onto inorganic zinc phosphate complex, which 
allows sustained release of ACTH after injection. Use of the depot preparation for ACTH stimulation has been 
studied in dogs as a possible alternative to regular Synacthen.(71, 75) Fourteen healthy dogs underwent 
repeated ACTH stimulation testing and serum cortisol concentration (mean ± standard deviation) after 1 hour was 
14.0 ± 4.4 µg/dL (385 ± 121 nmol/L) after 250 µg intramuscular Synacthen Depot versus 16.1 ± 4.0 µg/dL (443 ± 
110 nmol/L) after 5 µg/kg IV of Synacthen.(71) Despite the trend of a lower cortisol concentration after Synacthen 
Depot compared to Synacthen, the difference was not statistically significant. The lack of statistical significance 
could be due to low statistical power and is not evidence of equivalency between the two ACTH preparations. 
The same study found that serum cortisol concentrations continued to increase at 2 (t=2) and 3 (t=3) hours 
following the depot injection and the peak concentration occurred much later in the depot preparation. Notably, 
mean t=3 cortisol concentration after Synacthen Depot was significantly greater than concentrations at 1 and 1.5 
hours after Synacthen. Some healthy dogs in the study had t=3 cortisol concentrations after Synacthen Depot 
above 22 µg/dL (605 nmol/L), which would be suggestive of hyperadrenocorticism if regular Synacthen RI were 
applied. 
A second study examined Synacthen Depot administration in both healthy dogs and dogs with suspected 
hypoadrenocorticism or hyperadrenocorticism.(75) One goal of this study was to determine the time for cortisol to 
reach its peak serum concentration. For the 22 healthy dogs, peak cortisol concentrations occurred at 1 hour 
(n=1), 2 hours (n=4), 3 hours (n=11) and 4 hours (n=6), with the median being 3 hours after intramuscular 
Synacthen Depot administration. For the 14 dogs with suspected hyperadrenocorticism, the peak cortisol 
concentration occurred at 1 hour (n=1), 2 hours (n=5), 3 hours (n=6) and 4 hours (n=2), with a median of 3 hours. 
The median time to peak concentration in dogs suspected of having hypoadrenocorticism was 4 hours. The 
authors concluded that the time to peak cortisol concentration was unpredictable in individual dogs and multiple 
venipunctures would be required to be determine the maximum cortisol concentration, an impractical requirement 
for in-hospital testing. Similar to the earlier study, 2/22 healthy dogs had excessively high peak serum cortisol 
concentrations after Synacthen Depot, a finding that could be suggestive of hyperadrenocorticism if regular 
Synacthen RI were applied. The high cortisol concentration could be attributable to stress or sustained 
stimulation from the depot preparation and unfortunately, no comparison to regular Synacthen was made in this 
study. It is unknown whether the t=1 cortisol concentration or the peak cortisol concentration after Synacthen 
Depot would be the most useful value to diagnose hyperadrenocorticism. The use of Synacthen Depot was less 
problematical in diagnosing hypoadrenocorticism, as the 2 dogs with hypoadrenocorticism in the study had blood 
cortisol concentrations below 0.2 µg/L (5.5 nmol/L) at all time points (1, 2, 3, 4, 5, 6, and 20 to 24-hours).  
The results from the above two studies suggest that cortisol concentrations after Synacthen Depot administration 
cannot be interpreted using the same RI that were generated using Synacthen for the diagnosis of 
hyperadrenocorticism. Diagnosis of hypoadrenocorticism using Synacthen Depot may be a viable option based 
on the findings in 2 dogs.(75) Further research is needed to establish new RI after ACTH stimulation if Synacthen 
Depot is to be routinely used in the clinical setting. In Australia, there are currently no validated alternatives to 
Synacthen for performing ACTH stimulation tests in dogs. 
2.4.1.4 Compounded synthetic adrenocorticotropic hormone 
An Australian compounding pharmacy, Bova Aus, has introduced a compounded version of ACTH 
(tetracosactide), which is sold as an alternative to Synacthen with the claim that the preparation has equivalent 
hormonal activity. Tetracosactide contains the same 24 amino acid polypeptide as tetracosactrin (the active 
ingredient in Synacthen); however, no studies examining its use in dogs have been published. Sodium chloride is 
the only excipient in the Bova ACTH preparation.(76) 
Compounding pharmacies prepare drugs by combining, mixing or altering the active agent and other ingredients 
to meet the needs of an individual subject. The benefits of compounding include obtaining an appropriate dose 
for the patient’s size, reducing the number of tablets administered, providing liquid preparations for ease of 
administration, or omitting known ingredients to which the patient may be allergic. Other benefits of compounding 
pharmacies include maintenance of supply of an agent when the commercial supply is unavailable or cost 
prohibitive.  
Due to the small-scale production of compounded drugs, these preparations cannot be individually approved by a 
government regulatory authority in the same manner as mass-manufactured drugs. For this reason, the FDA 
recommends against using compounded medications when an FDA-approved alternative is available.(77) The 
quality of compounding pharmacies also varies, with one medical crisis in 2012 involving 753 cases of fungal 
meningitis in people resulting from administration of contaminated preparations prepared by the New England 
Compounding Center.(78) Such widespread consequences of contamination are partly attributable to 
compounding pharmacies expanding beyond their traditional role of filling individual prescriptions. Some 
companies, including Bova, can dispense tetracosactide under emergency supply scripts and without receipt of 
an individual patient prescription. ACTH stimulation testing can occur in emergency scenarios and thus patients 
are best served if ACTH is stocked by veterinary hospitals and is immediately available. Stocking Bova ACTH 
was originally feasible when the beyond-use-date was 90 days (including at the start of the study in 2017). In 
February, 2018, the beyond-use-date decreased to 3 days in accordance with the updated guidance on 
compounding of sterile injectable medicines published by The Pharmacy Board of Australia.(79) The updated 
guidelines suggested a much shorter beyond-use-date for sterile compounded injectables due to concerns 
regarding microbial contamination and stability of the active chemical compound. Bova accordingly reduced its 
beyond-use-date from 90 to 3 days after 1st February 2018, however no change to the compounding of the 
preparation occurred at this time.(76) The much shorter beyond-use-date is a significant logistical drawback for 
using the compounded ACTH preparation in small animal practice. 
2.4.2 Dose of adrenocorticotropic hormone  
A 5 µg/kg IV dose of ACTH is widely used for the ACTH stimulation test. Multiple studies have demonstrated that 
5 µg/kg of Cortrosyn is sufficient to stimulate maximal adrenal cortisol production, compared to an IV dose of 250 
µg/dog.(80-82)  
A recent study by Aldridge and others (2016) examined the possibility of using an even lower dose of ACTH, and 
compared 1 µg/kg versus 5 µg/kg IV for stimulation in healthy dogs (n=10), in dogs suspected of 
hyperadrenocorticism (n=39) and in dogs undergoing treatment with mitotane or trilostane (n=27).(73) In the 10 
healthy dogs, t=1 cortisol concentrations were considered equivalent, with the 90% CI of the ratio of the mean 
cortisol concentration calculated to be 86.6-99.3%, which was within the equivalence range of 80-125%. 
However, in the 39 dogs suspected of hyperadrenocorticism the 90% CI of the cortisol ratio was 73.2-92.8%, 
which was outside the equivalence range. Thus, lower doses of ACTH are not recommended for ACTH 
stimulation testing. 
2.4.3 Timing of ACTH testing 
In veterinary practice, 1 hour is often chosen for the cortisol measurement after ACTH administration, with the 
exact timing used for diagnostic purposes ideally adhering to the methodology recommended by the laboratory 
performing the cortisol assay. In essence, RI generated from samples taken 1 hour after stimulation should be 
used to interpret cortisol concentrations taken from patients after the same interval. Peak cortisol concentration 
typically occurs 60-90 minutes after IV injection of ACTH.(14, 80, 81, 83) 
An early publication by Feldman and others (1982) chose to measure plasma cortisol concentrations 1 hour after 
administration of intramuscular Cortrosyn and 2 hours after administration of intramuscular porcine ACTH in 16 
healthy dogs.(56) The post-stimulation values in Feldman’s study were subsequently used as the RI for cortisol 
concentrations 1 hour after ACTH stimulation in further studies of dogs with adrenal disease.(33) The wide-
spread acceptance of sampling 1 hour after ACTH administration assists comparison of results between different 
studies. 
2.4.4 Cortisol assay 
Various types of assays are available to measure cortisol concentrations, including radioimmunoassays and 
immunoassays. Radioimmunoassays are considered the gold standard for cortisol measurements, however they 
have fallen out of favour due to the short shelf lives of reagents and the possible radiation hazard for laboratory 
personnel.(84) Immunoassays are now commonly used, however canine validation studies are sparse. One 
study in dogs has compared a chemiluminescent assay (Immulite®, Diagnostic Products Corporation, Los 
Angeles, California, USA; later acquired by Siemens, München, Germany) to a radioimmunoassay (Coat-A-
Count®, Cortisol Radioimmunoassay Kit, Diagnostic Products Corporation, Los Angeles, California, USA).(85) 
Results from that study demonstrated cortisol measurements from the two assays were highly correlated, 
however, significant differences occasionally existed if concentrations were less than 100 nmol/L. 
Chemiluminescent assays utilise light emission readings to measure concentration, and presence of lipaemia or 
haemolysis can potentially result in assay interference. One in vitro study found that the addition of lipid or 
bilirubin resulted in significant changes to cortisol concentrations measured by an enzyme-linked immunosorbent 
assay (Enzymun-Test, Boehringer Mannheim).(86) It is important to note, however, that the magnitude of the 
difference caused by bilirubinemia or lipaemia was considered clinically insignificant. 
Manufacturers of cortisol assays also report upper limits for acceptable haemolysis, lipaemia or icterus in a 
sample submitted for analysis. For example, the manufacturer of a chemiluminescent assay (ADVIA Centaur® 
Cortisol assay, Siemens, München, Germany) report an insignificant effect on cortisol for haemoglobin 
concentrations up to 500 mg/dL (0.31 mmol/L), triglycerides up to 1170 mg/dL (30.3 mmol/L) and bilirubin up to 
20 mg/dL (342 µmol/L).(29) Cortisol concentrations measured by radioimmunoassay are reportedly unaffected by 
haemolysis or lipaemia.(87, 88) 
2.5 Statistical methods of demonstrating non-inferiority and equivalence 
The purpose, design and statistical analysis of non-inferiority and equivalence trials have been reviewed in both 
veterinary and human literature.(89-92) It is important to distinguish the purpose of non-inferiority trials from 
superiority trials. In a non-inferiority study, the aim is to demonstrate that the effect of the test drug is sufficiently 
close to and is at least as good as the control drug. A non-inferiority trial has the null hypothesis that the test drug 
is inferior to the control (i.e. opposite to that of a superiority trial). The alternative hypothesis is that the test drug 
is non-inferior, which usually forms the study aim. Another important difference in a non-inferiority study is that 
the clinical conclusion requires pre-determined criteria of what is an acceptable difference to conclude non-
inferiority.  
Non-inferiority and equivalence trials can have multiple applications, including accepting a newer treatment or 
test which is equivalent, but might pose advantages of being cheaper, easier to administer, more readily available 
or has fewer adverse effects than the reference under comparison. Another application of a non-inferiority study 
is when ethical concerns preclude the use of a placebo in diseases where a known effective treatment is 
available (and cannot ethically be withheld from test subjects). 
The determination of pharmacologic equivalence in living organisms is complicated by daily variations in 
biological functions (e.g. hormone secretion). Multiple factors can affect the rate of cellular synthesis of cortisol 
and the clearance of cortisol by the liver. The variation in synthesis or clearance may change the cortisol 
concentrations after stimulation with ACTH and confound equivalence comparisons across different test days. 
Two successive ACTH stimulation tests performed in the same dog using the same ACTH preparation would not 
be expected to result in identical blood cortisol concentrations due to these biological variations. Additional 
variance may also be introduced by the cortisol assay, which is quantified by coefficients of variation.  
A recent study examined the biological and analytical variability of canine cortisol concentrations and calculated 
the critical difference (defined as the smallest difference between sequential laboratory results in a subject which 
likely indicates a true change).(93) The critical difference in a group of 14 healthy harrier hounds was 92 nmol/L, 
meaning a change of cortisol concentration less than 92 nmol/L could be due to individual or laboratory variation 
rather a true difference in HPA response. Based on this information, any study design examining sequential 
cortisol concentrations in an individual should allow for this variation and not overinterpret this difference as 
clinically significant.  
Research design for non-inferiority and equivalence testing of pharmaceutical drugs has been extensively 
reviewed. The process of validating generic or compounded medications by use of non-inferiority trials has been 
the topic of a recent CONSORT (Consolidated Standards Of Reporting Trials) statement.(91) The FDA has also 
published a Guidance for Industry regarding non-inferiority clinical trials.(94) 
Both the FDA and CONSORT publications guide researchers through the process of research design and 
statistical analysis of non-inferiority and equivalence trials. The FDA Guidance for Industry distinguishes a non-
inferiority trial from an equivalence trial, in that a non-inferiority trial is one sided and its aim is to determine that 
the newer product is not materially worse than the control. It is not designed to detect whether the new product is 
superior. In comparison, an equivalence trial is designed to detect both inferiority and superiority of a product. 
In a study that aims to determine superiority (alternative hypothesis is that treatment is superior to control), one 
commonly used statistical test is the t-test, used to determine whether there is a significant difference, on 
average, between the test product and the control product. However, an equivalence study has the alternative 
hypothesis of no difference between the treatment and control, which requires a set of different statistical 
approaches. For example, the lack of a significant difference by using t-test analysis indicates an absence of 
difference but is insufficient to provide proof of equivalence or non-inferiority. 
Tests for correlation and variance are also less useful when attempting to determine the equivalence of two 
preparations, as results may correlate but still have poor agreement (for example, if one value was consistently 
half the magnitude of the other). In addition, any changing pattern to the agreement across the spectrum of 
measurements is not detected since the line of best fit, the regression line, does not take into account pairwise 
relationships, but simply divides the data points equally above and below the line of regression. Thus, correlation 
and lack of statistical difference are not useful terms in an equivalence or non-inferiority study. 
The FDA Guidance for Industry publication: Statistical Approaches to Establishing Bioequivalence, examines 
pharmacokinetic studies that are used to establish bioequivalence of drugs (usually a generic compared to a 
brand-name drug).(95) For pharmacokinetic studies, important measurement parameters are area under the 
curve and peak concentration and the FDA suggests a bioequivalence range of 0.8-1.25 for the 90% confidence 
interval (CI) of the ratio of the means of the drug concentration for drugs with a wide safety margin. The 
publication further recommends tailoring the equivalence region to suit the therapeutic and toxicity profile of the 
drug under examination. For example, a smaller range of variation would be necessary if variation of up to 25% 
could to lead to toxicity. ACTH at a dose of 5 µg/kg and the resulting cortisol response have no toxicity concerns; 
however, the main consequence of excessive variation in cortisol concentration is less accurate discrimination 
between ill and healthy dogs. The measure of equivalence under investigation in our study is the cortisol 
response rather than measuring ACTH concentration in a pharmacokinetic study. However, we have chosen to 
apply the same criteria for equivalency to the cortisol response.  
Statistical approaches for non-inferiority studies have also been reviewed in the veterinary field.(89, 96) Freise 
and others (2013) discussed the scientific basis of the pre-determined non-inferiority margin, which is ideally 
based on the smallest reliable effect size of the active control.(89) However, the smallest effect size of the control 
can only be derived from previously published, well-designed placebo controlled studies, which are often lacking 
in veterinary medicine. Without placebo studies, the pre-determined non-inferiority margin is based on clinical 
judgement, and a review of the veterinary non-inferiority studies reported the most common margins were ≤15% 
for percentages and 0.20 for ratios.(89)  A two-sided 95% CI of the difference between the effects of the active 
control and the test treatment can then be compared to the pre-determined margin of non-inferiority to determine 
if the new treatment is non-inferior.   
An older review by Christley and others (2003) discussed the use of Bland-Altman analysis, which provides a 
visual assessment of the agreement between two results.(96) Bland-Altman analysis plots the mean of the test 
and control results on the x-axis against the difference or ratio of the two results on the y-axis. The bias (mean 
difference or ratio) and 95% limits of agreement (bias ± 1.96 standard deviation of the bias) summarises the 
agreement between the test and control.(97) By visualising the difference between measured values, readers can 
assess for systematic bias, homoscedastic scatter (difference is constant across the range of values) or 
heteroscedastic scatter (differences increase with increasing magnitudes).  
2.6 Previous studies of compounded adrenocorticotropic hormone 
A North American study by Kemppainen and others (2005) compared 4 compounded synthetic ACTH 
preparations to Cortrosyn in 5 healthy dogs.(72) The study concluded that the serum cortisol concentrations 
stimulated by compounded ACTH were not significantly different from that stimulated by Cortrosyn administration. 
This lack of significance, however, could possibly be due to the study’s low power. Examining the data directly 
suggests that there were differences present among the cortisol concentrations after ACTH stimulation. In one 
discordant example, the upper limit of cortisol concentration 1 hour after Cortrosyn was approximately 430 nmol/L 
(estimated from a box plot) versus 600 nmol/L after ACTH compounded by Wedgewood Pharmacy, New Jersey, 
USA. Despite such apparent discordance in mean cortisol concentrations 1 hour after ACTH stimulation, the 
difference was not statistically significant. As previously mentioned, a t-test comparison is not a test of agreement 
and failure to find a difference in concentrations, on average, does not imply equivalence. 
Low statistical power was also a major limitation of the pilot study by Hill and others (1985), which compared 
Cortrosyn to a compounded ACTH gel (Corticotropin for injection, Hook’s apothecary, Indiana, USA) in 5 healthy 
dogs and 4 dogs with clinical signs of hyperadrenocorticism or hypoadrenocorticism.(98) No statistically 
significant differences between cortisol concentrations were identified, however 1 dog with suspected 
hyperadrenocorticism had a serum cortisol concentration of 26.2 µg/dL (720.5 nmol/L) after Cortrosyn versus 17 
µg/dL (467.5 nmol/L) after a compounded ACTH gel. The magnitude of the difference in cortisol concentration 
between the two post-stimulation tests (Cortrosyn versus the compounded ACTH gel) could be enough to alter 
the diagnosis from hyperadrenocorticism to normal adrenal function, depending on the cut-off concentrations 
used by the individual laboratory. 
In summary, previous studies have recorded variation in the cortisol concentrations after compounded ACTH 
preparations compared to standard ACTH.(72, 98) However, although the variations did not create significant 
differences in results between compounds, the variation could be clinically significant and alter the diagnosis of 
abnormal versus healthy adrenal function in an individual dog, depending on the cut-off concentration used by 
the laboratory. Despite the discordant results, the lack of a statistically significant difference led to the 
questionable conclusion by Kemppainen and others that compounded ACTH preparation resulted in equivalent 
serum cortisol concentrations compared to Cortrosyn. The only interpretation they can make, is that on average, 
the cortisol concentrations were not different but that they have not examined equivalence or agreement, and the 
small number of dogs in the study precluded any definitive conclusions. Determining equivalence requires careful 
consideration of statistical analysis. Standard hypothesis testing methods are unsuitable for testing equivalence 
and poorly powered studies can erroneously support the null hypothesis of no difference (type II error) which 
simply infers the failure to find a difference, not proving similarity. Lastly, it should be noted that none of the 
compounded preparations studied in the USA are available in Australia.  
  
2.7 Cortisol variability and subject characteristics 
Subject characteristics affecting the HPA axis have been investigated in many species and include 
characteristics such as sex, neuter status, age, obesity, reproductive cycle, blood albumin concentration and 
cortisol-binding globulin concentrations. The associations identified in various studies are sometimes 
contradictory and the pathophysiology of many associations is poorly understood. Other features that make 
interpretation difficult include poor standardisation in study design and differing methods for assessing the HPA 
axis. Another limitation in the studies is the difficulty in accounting for the different variables on cortisol 
concentrations with multivariable analysis. The large-scale studies in people allow adjustments for the effect of 
sex, age and obesity, etc.; however, this is more difficult when attempting similar assessments in smaller canine 
studies. 
2.7.1 Blood proteins 
Free cortisol is described in people as the hormonally active portion and is not bound to plasma proteins such as 
cortisol-binding globulin and albumin.(99, 100) Alterations in cortisol-binding globulin or albumin can affect the 
amount of free active cortisol in circulation and also affect measurements of total cortisol concentrations.(100, 
101) In people, cortisol-binding globulin is present in low concentrations in the blood (low capacity) but binds 
cortisol with high affinity; by comparison albumin is in high concentrations in blood (high capacity) but binds with 
low affinity.(101)  
A similar situation is believed to be present in dogs, where the majority of cortisol in circulation is protein-
bound.(102) Studies have investigated the cortisol-binding capacity in blood and estimated the proportion of free 
cortisol concentration using ultrafiltration and equilibrium dialysis techniques.(103-106) Free cortisol measured by 
centrifugal ultrafiltration-dialysis comprised 13 ± 6% (mean ± SD) of the total cortisol concentration measured by 
radioimmunoassay in 18 healthy dogs.(104) A similar study in 40 healthy dogs measured free cortisol to account 
for 8.2 ± 2.3% (mean ± SD) of the total cortisol concentration.(107) Two studies have found that the cortisol 
binding capacity in dogs is not heat labile, differing to human cortisol-binding globulin.(104, 105) The difference 
suggests a difference in the protein structure responsible for cortisol binding in the two species, however the 
exact structure of cortisol-binding globulin in dogs is unknown and a direct test for canine cortisol-binding globulin 
is unavailable.(107) 
One study examined a state of altered protein synthesis and found that dogs with hepatic encephalopathy 
secondary to a portosystemic shunt had a greater proportion of free cortisol compared to healthy dogs.(107) The 
authors conjectured that the increased free cortisol was evidence for decreased blood concentration of cortisol-
binding globulin, which is normally synthesised by the liver. In the same study, the percentage of free cortisol in 
plasma was not significantly correlated with plasma albumin concentration. Studies in people with severe 
hepatitis have found significantly higher free cortisol and lower corticosteroid-binding globulin and albumin 
concentrations compared to healthy controls.(108) It is thought albumin concentrations in healthy people have 
very little effect on total blood cortisol concentrations as albumin only binds a small portion of protein-bound 
cortisol.(100)  
A small number of studies in people have also described erythrocyte-associated cortisol, however results are 
conflicting regarding the importance of this component in determining cortisol activity.(109-111) Various methods 
are available to calculate the proportion of erythrocyte-associated cortisol but these methods have not been 
thoroughly validated.(109, 112) Given the difficulties of measuring free cortisol, most studies only measure total 
cortisol concentration. 
2.7.2 Sex 
The difference in HPA function between the sexes is inconsistent across studies. Some studies have reported 
higher basal cortisol concentrations and HPA response in men and male animals,(93, 113, 114) while other 
studies have found higher cortisol concentrations in women and female animals.(22, 115, 116) Some studies in 
dogs and people have found no difference between the sexes when analysing basal cortisol concentrations or 
ACTH stimulation results.(117, 118) The contradictory conclusions may be due to variable study design, the use 
of different tests to assess the HPA axis and non-standardised study populations with confounding characteristics 
affecting cortisol concentrations. For example, one possible confounding characteristic is the reproductive state 
of the female at the time of testing, which is discussed further in 2.7.3. 
When examining basal concentrations, a slightly greater mean serum cortisol concentration (averaged over 
different time points) was noted in male dogs compared to female dogs in a group of 14 harrier hounds 
(comprising of 8 entire females, 1 neutered female, 1 entire male and 4 neutered males).(93) Basal cortisol 
concentrations (mean ± SD) in male dogs measured 366 ± 114 nmol/L versus 318 ± 65 nmol/L in female dogs, 
with the difference being statistically significant (p = 0.046). By contrast, an experimental study measuring 
plasma cortisol concentrations every 20 minutes over 24 hours in 4 anoestrous female and 5 entire male dogs 
identified a significantly higher 24-hour mean cortisol concentration in the females.(22) In contrast to these 
findings, no difference in mean basal serum cortisol concentration was detected between the sexes in a 
comparison study of 556 healthy female and 515 healthy male dogs (of unknown neuter status).(119) Similarly, 2 
separate studies found no difference between sexes in serum basal cortisol concentration in 18 healthy dogs (5 
entire females, 7 neutered females, 4 entire males, 2 neutered males)(120) and 49 healthy dogs (35 males and 
14 females of unknown neuter status).(117) 
Other studies have examined the influence of sex on cortisol concentrations after ACTH stimulation, which 
removes the influence of the unpredictable daily fluctuations in basal cortisol concentrations and thus, reduces 
the chance of a type I error. An example of how conclusions can differ depending on the assay was 
demonstrated in one study of beagles in a research facility.(121) The study found significantly higher basal serum 
cortisol concentrations in female compared to male beagles, however, cortisol concentrations after ACTH 
stimulation in the same group of dogs were not significantly different between the sexes. Thus, the results within 
this single study disagree over the presence of a sex-based difference depending on the test used. As there is no 
gold standard test, the true effect of sex on the HPA axis remains unknown. Lastly, a small study found females 
had significantly higher plasma cortisol concentration 1 to 2 hours after ACTH stimulation, when comparing 4 
female with 3 male cocker spaniels.(115)  
Studies in people have also not used standardised methodology when examining the HPA axis, which may be 
one reason for the varying conclusions regarding the presence of a sex-based difference. Blood cortisol 
concentrations after ACTH stimulation in two studies were not significantly different between men and 
women.(118, 122) Another study found that elderly women had significantly higher serum cortisol concentrations 
after ACTH stimulation compared to elderly men (70 to 92 years).(116) The same test in a younger cohort (21 to 
58 years) found no difference between the sexes, suggesting a sex-based difference in HPA response may be 
age dependent in people. Another study found significantly higher free serum cortisol concentrations after ACTH 
stimulation in men compared to women, but the same comparison of basal serum cortisol concentrations found 
no significant difference between the sexes.(114) Another study in 24 men (mean age ± SD, 29.3 ± 5.1 years) 
and 19 women (mean age ± SD, 27.3 ± 5.7 years) administered corticotropin releasing hormone (CRH), which 
showed women had a higher plasma ACTH concentration response than men, however the cortisol 
concentrations after CRH stimulation were similar between women and men.(123)  
Other studies have assessed overall cortisol production by measuring blood cortisol concentrations over 24 hours 
with indwelling intravenous catheters, or by measuring urinary cortisol excretion. Both forms of measurement are 
aimed at minimising the impact of sampling stress on cortisol concentration and provide information throughout 
the diurnal cycle.(113) One study measuring mean plasma cortisol concentration every 20 minutes for 24 hours 
reported a statistically higher mean cortisol concentration in men (11.6 µg/dL) than in women (8.5 ug/dL).(113) A 
separate study of 24-hour urinary free cortisol excretion also found significantly higher cortisol in men than 
women.(124) In comparison, another study found plasma cortisol concentrations were not significantly different 
between elderly men and women when comparing basal cortisol concentrations at 4-hourly intervals.(125)  
In rats, experimental stress-induced corticosterone was measured to be higher in females than males(126); and 
ACTH stimulation also resulted in higher plasma corticosterone concentrations in female than male rats.(127) 
A study in 24 sheep found plasma cortisol concentrations after ACTH stimulation to be higher in females than 
males.(128) Another study of 16 sheep found cortisol response to insulin-induced hypoglycaemia was greater in 
males than in females, however the opposite occurred after experimental stress (isolation and restraint), which 
resulted in a greater cortisol response in females than males.(129) The same study found that cortisol 
concentrations after ACTH stimulation were not significantly different between the sexes.(129) The disparate 
results highlight how different conclusions can be drawn regarding the HPA axis solely based on varying test 
methodologies. The gold standard for testing the HPA axis has not been established in animals. 
2.7.3 Oestrus cycle 
The oestrus (or menstrual) cycle is associated with differing concentrations of blood oestrogen and progesterone, 
which in turn can affect the HPA axis. The interactions of endogenous progesterone, oestradiol and other sex 
hormones on the HPA axis is still under study and not fully understood.  
Progesterone can activate glucocorticoid receptors and thus cause negative feedback to the HPA axis. An in vitro 
experimental study of dog tissue found that medroxyprogesterone acetate (a synthetic progestin) had a high 
affinity for glucocorticoid receptors.(130) In vivo experiments in 16 ovariohysterectomised dogs demonstrated 
that administration of medroxyprogesterone acetate and proligestone (two types of synthetic progestins) resulted 
in suppression of basal plasma cortisol and ACTH concentrations.(131) Administration of medroxyprogesterone 
acetate to 5 entire female Beagles also resulted in HPA axis suppression, with significantly lower cortisol 
concentrations after CRH stimulation, compared to results obtained prior to medroxyprogesterone acetate 
administration.(132) A separate study in cats that were administered the synthetic progesterone megesterol 
acetate also showed suppressed cortisol concentration after ACTH stimulation.(133)  
The aforementioned experimental studies demonstrate the effect of synthetic progestins and hint at the potential 
effect of endogenous progesterone on the HPA axis. Progesterone fluctuations in entire female dogs reach a 
peak in dioestrus or pregnancy. Progesterone is lowest in entire female dogs during anoestrus. If endogenous 
progesterone were similar in effect to the exogenous progestins, then female dogs in dioestrus would be 
expected to have lower blood cortisol concentrations (due to negative feedback from high progesterone 
concentrations) compared to female dogs in proestrus. 
This possible effect of progesterone was not supported by a study in 30 beagles, which compared female dogs in 
different stages of the reproductive cycle (anoestrus, proestrus, dioestrus, lactation, pregnancy) and male dogs 
after ACTH stimulation testing.(134) The study found a significant difference between groups; however, the 
difference contradicted the theory that progesterone suppresses the HPA axis. The study found that female dogs 
in anoestrus and diestrus had significantly higher mean serum cortisol concentrations after ACTH stimulation 
than lactating or pregnant female dogs, or males. Female dogs in proestrus had significantly lower serum cortisol 
concentration than all other groups. The authors hypothesised that female dogs in dioestrus may be more 
sensitive to stress and thus had higher cortisol concentrations, but this theory was not supported by other 
research. As the study compared groups of different dogs, inter-individual variability may have confounded the 
results. A better study design could have used each dog as its own control and followed each subject through the 
oestrus cycle to better compare HPA variation due to reproductive status. 
Another study found that morning serum cortisol concentrations were significantly higher in men than in women in 
their follicular phase, but there was no significant difference between men and women in their luteal phase.(135) 
The difference in findings between women in their follicular versus luteal phase suggested sex hormones may 
have an influence on serum cortisol concentrations.  
Studies in rats found significantly higher peak ACTH and corticosterone concentration in rats exposed to stress 
when they were in proestrus compared to dioestrus or oestrus, a finding which is opposite to that found in dogs. 
(136) It is unclear whether there is a true species difference or if the difference is due to study variability.  
2.7.4 Neutering 
As progesterone and oestradiol are believed to influence the HPA axis, it is reasonable to expect changes 
resulting from neutering and removal of the sex hormones. There is minimal research in this area due to the 
limited clinical relevance to people. A study of 97 dogs found that entire male dogs (n=20) had lower serum 
cortisol concentrations after ACTH stimulation compared to neutered male (n=30), entire female (n=17) and 
neutered female dogs (n=30).(137) Basal serum cortisol concentrations among the 4 groups were similar. The 
reason for lower cortisol concentrations in entire males is unknown and there have been no further studies to 
confirm whether a true difference after ACTH stimulation exists in entire male dogs. 
A small study in 16 sheep found no difference between entire versus neutered animals in cortisol responses to 
insulin-induced hypoglycaemia or isolation/restraint stress.(129) Conversely, another study in 24 sheep found 
neutering reduced the cortisol response to ACTH stimulation in females but not in males.(128) 
2.7.5 Obesity 
A recent literature review of the association between obesity and the HPA axis was inconclusive regarding both 
association and causation.(138) Many of the reviewed studies reported increased basal cortisol concentrations 
and/or HPA response to be associated with increased abdominal fat, however opposing studies have associated 
decreased basal cortisol concentrations with obesity. The majority of studies examining obesity and the HPA axis 
have been conducted in people, rats and sheep.(139) There are no published studies examining obesity and the 
HPA axis in dogs. A study in 56 clinically normal dogs found no difference in basal serum cortisol concentrations 
based on body weight (6.7 to 13.5 kg versus 13.5 to 27 kg) or breed, however body condition scores were not 
reported.(117) 
A variety of studies using different methodologies have examined obesity and the HPA axis in people. Higher 
basal serum cortisol concentrations have been reported in obese women compared to women of normal 
bodyweight,(140) and increased blood cortisol after ACTH stimulation was also found in men with waist-to-hip 
ratios of greater than 0.95 compared to men with ratios less than 0.95.(141) The distribution of body fat may also 
be important: obese women with abdominal fat distribution (n=12) had significantly higher plasma cortisol 
concentrations 60 minutes after ACTH stimulation than obese women with peripheral fat distribution (n=13).(142) 
The same study also found a significantly higher daily urinary free cortisol excretion rate in obese women with 
abdominal fat distribution. By comparison, Hankin and others (1972) found no difference in 24-hour urinary 
excretion of free cortisol in 23 non-obese versus 23 obese women.(143) In another study, salivary cortisol 
concentration after a stressful incident was associated with sagittal trunk recumbent diameter (p=0.05), however 
waist-to-hip ratio and body mass index did not reach any statistically significant association.(144)  
In contrast, a few studies have found obesity to be associated with decreased cortisol concentrations. Strain and 
others (1982) described decreased 24-hour mean plasma cortisol concentrations in obese women compared to 
non-obese women.(145) No significant difference was found in obese versus non-obese men in the same study. 
The same authors also demonstrated a significantly increased metabolic clearance rate for cortisol in obese 
women compared to non-obese women, suggesting that increased clearance was responsible for the lower 
cortisol concentration. Another study found that in a group of highly stressed women, sagittal diameter was 
negatively correlated with morning and evening basal salivary cortisol concentrations, i.e. that obesity in 
combination with stress was associated with a relative hypocortisolaemia.(146) 
The conflicting conclusions from different studies highlight the lack of standardisation in assessing both the HPA 
axis and obesity in people and the differences preclude direct comparisons between studies examining the link 
between HPA dysfunction and obesity. There is no consensus on the ideal test for HPA dysfunction, the most 
common methods being basal cortisol concentrations, urinary cortisol concentrations, salivary cortisol 
concentrations, ACTH stimulation testing, CRH stimulation testing and stress-induced cortisol testing. Similarly, 
obesity is defined differently between studies. A general measure of obesity is body mass index, however waist-
to-hip ratio is thought to be a more accurate index for abdominal obesity and does not necessarily correlate with 
body mass index.(138) Based on the available studies, it remains unclear whether HPA dysfunction precedes 
obesity or whether obesity precedes HPA dysfunction.  
In sheep, obese females were found to have higher cortisol and ACTH concentrations in response to isolation 
and restraint stress compared to lean females.(147) When examined from another angle, female sheep with a 
high cortisol response after ACTH stimulation (high cortisol responsiveness) were at increased risk of obesity 
when compared to sheep with low cortisol response after ACTH stimulation.(148, 149) The same studies found 
that sheep with high cortisol responsiveness had reduced skeletal muscle thermogenesis which is one possible 
mechanism for the increased risk of weight gain.(148, 149)  
2.7.6 Diet 
Dietary components may also affect the HPA axis although the exact mechanism is unknown. Markus and others 
(2000) reported that 11 self-assessed high stress men and women had lower salivary cortisol concentrations 
after laboratory-induced stress after eating a high-carbohydrate, low-protein diet, compared to a control group of 
11 people who ate a low-carbohydrate, high-protein diet.(150) A small study of 6 healthy people found no change 
in plasma cortisol after eating a lactovegetarian diet for 5 days compared to eating a moderately protein-rich non-
vegetarian diet for 5 days.(151) However, the same study found urinary 24-hour free cortisol concentration was 
significantly reduced in people eating the lactovegetarian diet. The disparate findings in the same study are 
difficult to interpret given the lack of a gold standard for assessing the HPA axis.  
Multiple studies have been performed in rodents examining the role of diets on the HPA axis; however, study 
results are inconsistent. The effect of a sucrose-rich diet was examined in rats, by offering the study group 30% 
sucrose added to their water, whilst the control group had normal water (both groups received the same feed). 
The rats with a high sucrose intake had higher basal plasma ACTH and serum corticosterone concentrations 
compared to the control group.(152) Another study found higher basal serum corticosterone but lower 
corticosterone after ACTH stimulation in rats fed a sucrose-rich diet (access to only water with 30% sucrose) 
compared to a control diet (access to normal water).(153) A separate study also reported significantly higher 
plasma basal and stress-induced corticosterone concentrations in rats fed a high-fat (20% fat) diet compared to a 
low-fat (4% fat) diet.(154)  
A study in 108 feedlot steers aimed to modulate the immune system with two types of specially formulated feeds 
containing transfer factor proteins, heteropolysaccharides, probiotics, vitamins, minerals and other proprietary 
ingredients.(155) Two groups of steers that were fed each of the immunomodulatory feeds had lower plasma 
cortisol concentrations compared to a third placebo control group. However, the lower cortisol did not equate to 
any clinical benefit, and the groups fed the immunomodulatory feed recorded decreased average daily growth 
and feed efficiency compared to the placebo group. There was also no significant difference in the incidence of 
bovine respiratory disease between the three groups. This study demonstrates how the dietary effects on the 
HPA axis, and the clinical consequences are still relatively unknown and require further research. 
2.7.7 Age 
Studies suggest there is limited effect of age on the HPA axis, though some studies do find some minor 
differences between age groups. A study in 56 clinically normal dogs found no difference in basal serum cortisol 
concentrations when comparing dogs below versus above 3 years old.(117) There have been no further canine 
studies examining the effect of age on the HPA axis.  
Ohashi and others (1986) found no difference in cortisol response after ACTH administration between young (24 
to 27 years) and old (60 to 68 years) men and women.(156) Similarly another study comparing a group of 
younger (21 to 58 years) versus older (70 to 92 years) men and women found no significant difference in serum 
cortisol concentrations after ACTH stimulation.(116) In contrast, another study found that slightly higher plasma 
cortisol concentrations occurred in older (51 to 89 years) compared to younger (18 to 42 years) men and women 
after ACTH stimulation.(122) It is evident that each study has a slightly different definition of elderly versus young 
people, which may be one explanation for the different results. 
Other studies in people have used alternative tests to assess the HPA axis, such as measuring basal plasma 
cortisol concentration,(157) performing low-dose dexamethasone suppression,(158) high-dose dexamethasone 
suppression and/or CRH stimulation.(159) There was no effect of age on basal plasma cortisol concentrations in 
women,(157) however a separate study found a trend towards higher basal evening cortisol concentration in 
older men.(160) The low-dose dexamethasone suppression test was not affected by age according to two 
separate studies(158, 159) and the CRH stimulation test was also found to be unaffected by age.(158)  
In a study of 16 healthy horses, elderly horses (18 to 24 years) were found to have significantly higher basal 
plasma ACTH concentrations, but basal plasma cortisol concentrations were not significantly different when 
compared to adult horses (5 to 13 years).(161) These results suggest that age-appropriate RI may be needed for 
horses, but this finding cannot be extrapolated to other species based on the current evidence. 
2.7.8 Seasonality 
ACTH variation in response to the seasons is described in horses, but not in dogs or people. Studies in horses 
have found seasonal differences in basal cortisol concentrations(161) and plasma ACTH concentrations after 
thyrotropin-releasing hormone stimulation.(162) These results may represent a true biologic difference between 
the species, but it is also possible that a circannual rhythm is easier to detect in horses. The outdoor housing of 
horses mean they more readily align their circannual rhythms to the seasonal photoperiods and environmental 
temperatures. 
2.7.9 Cytokines 
Current evidence suggests there is bidirectional communication between the immune and neuroendocrine 
systems. It is well known that glucocorticoids affect the immune system, but research also shows that the HPA 
axis is modulated by cytokines.(163) Although the association between HPA axis and cytokines is demonstrated 
in rodents and people, similar studies in dogs have not been performed.  
Many rodent studies confirm HPA stimulation (increases in blood ACTH and/or CRH and/or corticosterone) after 
administration of exogenous tumour necrosis factor-α (TNF-α),(164, 165) interleukin-1 (IL-1),(166-169) and 
interleukin-6 (IL-6).(170, 171) Research also suggests Leukaemia-Inhibitory Factor also has an important role in 
HPA stimulation. Leukaemia-Inhibitory Factor knockout mice had lower basal ACTH concentrations,(172) and 
decreased response to stress compared to wild-type mice.(173) Numerous studies have suggested that the HPA 
stimulatory effects by cytokines are primarily mediated via CRH release at the level of the hypothalamus.(165, 
171) Further studies also suggest the presence of an alternative pathway linking the HPA axis and cytokine 
production. CRH receptor-deficient mice can still produce corticosterone in response to inflammation 
(experimentally injected turpentine), demonstrating that glucocorticoid production is possible in the absence of 
normal HPA signalling.(174). Another rodent study demonstrated IL-6 receptors by immunofluorescence on 
corticotrophs, suggesting that direct pituitary stimulation by IL-6 is also possible.(175) 
There are fewer studies in people examining the interaction between cytokines and the HPA axis. One 
experimental study injected cancer patients with recombinant IL-6, which resulted in significantly increased 
plasma ACTH and cortisol concentrations.(176) HPA stimulation after IL-6 injection paralleled the earlier findings 
from rodent studies that also demonstrated increased plasma ACTH concentrations after IL-6 injection.(170, 171) 
Glucocorticoids are usually considered immunosuppressive and play a role in homeostasis via glucocorticoid-
mediated negative feedback on cytokines, including IL-1 and TNF-α. A broader range of effects by 
glucocorticoids is also possible, with studies that associate acute and chronic stress with increased IL-6 and 
interleukin-1β in rats and people, although the exact mechanisms of interaction are still being investigated.(163, 
177, 178) 
2.8 Conclusion 
The HPA axis is a complex signalling cascade and regulates cortisol and other hormone concentrations. 
Dysfunction of the HPA axis results in diseases including hypoadrenocorticism and hyperadrenocorticism and 
diagnosis of these diseases requires specialised assays. One such assay, the ACTH stimulation test, requires 
administration of an exogenous form of ACTH. Compounded ACTH increases the availability of testing by 
practising veterinarians, however, compounded ACTH should be verified to produce equivalent results compared 
to commercial ACTH prior to general use.  
When testing the HPA axis, veterinarians and scientists should also consider how subject variables can influence 
cortisol concentrations. The studies to date provide intriguing clues regarding the interconnection between 
subject characteristics and the HPA axis. These interactions need to be better understood to improve 
interpretation of HPA axis studies as well as results from individual testing. If subject characteristics such as sex 
or reproductive status are responsible for some of the variation of cortisol concentrations after ACTH stimulation, 
then RI can be tailored accordingly to increase sensitivity and specificity of diagnosing endocrine disease. 
  
3. Biochemistry validation 
As part of the equivalence study to enrol healthy dogs, biochemical analysis was planned as a component of the 
health screen. An on-site biochemistry machine, COBAS INTEGRA® 400 plus analyser (Roche, Basel, 
Switzerland), was available for use, however there were no canine RI for this machine.  
The process of generating RI for the COBAS INTEGRA was based on guidelines published by the American 
Society for Veterinary Clinical Pathology (ASVCP),(179, 180) which in turn were based on the Clinical and 
Laboratory Standards Institute (CLSI) guidelines used in people.(181) These guidelines help produce relevant RI 
appropriate for the test population and maximise the sensitivity and specificity of each analyte. New analyser 
machines require either validation of previous RI or generation of new RI, using animals that are representative of 
the local population. Seventeen biochemical analytes were selected for the health screen panel and RI for these 
17 analytes were created for the COBAS INTEGRA.  
3.1 Methodology  
Quality control was performed as per the manufacturer’s instructions prior to each day of analysis. The samples 
were processed according to manufacturer’s instructions. The 17 biochemical analytes selected were sodium 
(Na), potassium (K), chloride (Cl), alanine transaminase (ALT), aspartate transaminase (AST), alkaline 
phosphatase (ALP), γ-glutamyltransferase (GGT), glucose, calcium, phosphorus, creatinine, urea, total protein, 
albumin, bilirubin, cholesterol, and triglyceride. 
RI for the COBAS INTEGRA were generated via two methods. Firstly, RI from a local commercial laboratory 
(which used an AU480 Chemistry Analyser [Beckman Coulter, Brea, California, USA]), were tested for suitability 
of transference to the COBAS INTEGRA. For analytes that failed the transference requirements, de novo RI were 
generated. The transference methodology was based on the ASVCP reference interval guidelines: Determination 
of de novo reference intervals in veterinary species and other related topics.(179, 180) As per ASVCP guidelines, 
plasma from 20 healthy dogs underwent biochemical analysis using the COBAS INTEGRA and their results were 
compared to the commercial laboratory RI. The dogs were determined to be healthy based on history and 
physical examination and were participating in separate studies aimed at generating RI for other machines 
(ethics permit R2932/17, Protocol ID number 380); surplus plasma from these studies were used in this current 
study. Plasma samples were visually checked for haemolysis or lipaemia and samples were excluded if either 
were present.  
As per the ASVCP and CLSI guidelines, if 2 or fewer of the 20 dogs had measurements outside of the candidate 
RI, the RI was considered transferable. This represents approximately 90% of a healthy population being within 
the RI. If 3 or 4 dogs were outside the RI, another 20 dogs could be tested and interpreted as above. If more than 
4 dogs fell outside the candidate RI, then transference was rejected. For the parameters that could not have RI 
transferred, new RI were generated by using the plasma from a larger group of healthy dogs,(180) using 
Reference Value Advisor version 2.1 on Microsoft Excel (Microsoft, Redmond, Washington, USA).(182) The 
Reference Value Advisor software automatically generates RI using five methodologies simultaneously. Standard 
parametric and robust Horn methods were applied to untransformed and Box-Cox transformed data. The 
parametric method assumes the data to be Gaussian in distribution. By comparison, the robust Horn method is 
recommended for small sample sizes, with symmetrical, but not necessarily Gaussian distribution.(183) The data 
was tested for symmetry prior to using the robust method, and a p value greater than 0.05 indicated no significant 
deviation from symmetry.(184) The histograms were also examined visually for symmetry.(182) Lastly, 
nonparametric methods (which make no assumptions about data distribution) were used to calculate RI when 
sample sizes were greater than 40.  
During analysis, the data was screened for potential outliers by visually examining box and whisker plots and via 
Tukey’s test which is part of the statistical processing by Reference Value Advisor. Tukey’s test flags values as 
potential outliers if a value is more than 1.5 times the interquartile range (the difference between the third and first 
quartile) from the quartiles. In order words, a value 1.5 times the interquartile range below the first quartile or 1.5 
times the interquartile range above the third quartile.(185) The limitation is that Tukey’s test assumes the data to 
be Gaussian when calculating the median and interquartile range. Any outliers flagged by Tukey’s method were 
manually examined for the likelihood that it is an aberrant observation. The CLSI guidelines recommend retaining 
outliers unless it is certain they represent aberrant observations.(181) 
Once RI were generated by the Reference Value Advisor, results were then manually selected for the method 
that generated the narrowest 90% CI of the lower and upper limits. For each analyte, the width of the CI of the 
upper and lower limit was also divided by the width of the RI. This ratio indicates the degree of inaccuracy of the 
newly generated RI. 
Another measure of precision is the coefficient of variation (CV), which were not calculated as part of this study, 
but the published CV from the COBAS INTEGRA manufacturer are listed in Table 5.
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Table 5 Coefficients of variation published by Roche for the COBAS INTEGRA analytes.(186) Na, sodium; K, potassium; Cl, chloride; ALT, alanine transaminase; AST, 
aspartate transaminase; ALP, alkaline phosphatase; GGT, γ-glutamyltransferase; Bil, bilirubin; Chol, cholesterol; Trig, triglyceride; Creat, Creatinine; TP, total protein; Alb, 
albumin; Phos, phosphate 
3.2 Results 
Seventeen biochemical parameters were assayed for 20 healthy dogs (Table 6 and Table 7) and compared to 
the RI from the commercial laboratory (Table 9). Of the total 17 biochemical parameters, 6 parameters 
(potassium, chloride, AST, glucose, calcium and phosphorus) had all values within the RI undergoing validation; 
2 parameters (creatinine and urea) had 1 dog outside of the RI undergoing validation and 3 parameters (ALP, 
GGT and total protein) had 2 dogs outside of the RI undergoing validation. These 11 parameters were 
considered to have acceptable RI to be transferred for use with the COBAS INTEGRA analyser.  
Six biochemical analytes were unacceptable for transference and new RI were generated for sodium, ALT, 
bilirubin, cholesterol, triglyceride, and albumin concentrations. The data from the initial 20 healthy dogs and 31 
additional healthy dogs resulted in a total of 35 measurements for sodium, 41 measurements for ALT, 39 
measurements for triglyceride, 40 measurements for cholesterol, 42 measurements for albumin and 31 
measurements for bilirubin (Table 9 and Table 10), which formed the basis of the new RI. The narrowest CI was 
produced when using the nonparametric method for ALT and cholesterol; and the robust method after Box-Cox 
transformation for sodium, triglyceride, albumin and bilirubin (Table 12). Data for sodium, triglyceride and albumin 
were tested for symmetry and had p value >0.05. The p value for the bilirubin dataset was 0.008, indicating 
statistically significant deviation from symmetry. However, the histogram after Box-Cox transformation was 
inspected and appeared reasonably symmetrical (Appendix 1) and the use of the robust method was retained. 
The CI was more than 0.2 times the width of the RI for the lower limit of sodium, and the upper limit of bilirubin 
and triglyceride (Table 12). One bilirubin measurement (Dog R9, bilirubin 2.8 mmol/L) was flagged as a suspect 
outlier using Tukey’s test 
 Age Sex Neuter status Breed 
Dog R1 4 M Neutered Kelpie cross 
Dog R2 6 M Neutered Miniature pinscher cross 
Dog R3 1 M Neutered German shepherd 
Dog R4 8 M Neutered Labrador cross 
Dog R5 3 M Entire Rottweiler 
Dog R6 1 F Neutered Labrador cross 
Dog R7 3 M Entire Bernese mountain dog 
Dog R8 5 F Neutered Bernese mountain dog 
Dog R9 7 F Neutered Standard poodle 
Dog R10 8 F Neutered Poodle cross 
Dog R11 4 M Neutered Staffordshire terrier cross 
Dog R12 3 F Neutered Red heeler cross 
Dog R13 4 M Neutered Kelpie cross 
Dog R14 3 M Neutered Shar-pei cross 
Dog R15 2 M Neutered Golden retriever 
Dog R16 5 M Neutered Rottweiler 
Dog R17 4 M Entire Brittany spaniel 
Dog R18 5 F Neutered Border collie 
Dog R19 4 F Entire Border collie 
Dog R20 1 F Entire Akita 
Table 6 Signalment of 20 healthy dogs used to validate reference intervals for transference to COBAS INTEGRA 
Table 7 Signalment of 20 healthy dogs used to validate reference intervals for transference to the COBAS 
INTEGRA analyser
 Age Sex Neuter status Breed 
Dog R1 4 M Neutered Kelpie cross 
Dog R2 6 M Neutered Miniature pinscher cross 
Dog R3 1 M Neutered German shepherd 
Dog R4 8 M Neutered Labrador cross 
Dog R5 3 M Entire Rottweiler 
Dog R6 1 F Neutered Labrador cross 
Dog R7 3 M Entire Bernese mountain dog 
Dog R8 5 F Neutered Bernese mountain dog 
Dog R9 7 F Neutered Standard poodle 
Dog R10 8 F Neutered Poodle cross 
Dog R11 4 M Neutered Staffordshire terrier cross 
Dog R12 3 F Neutered Red heeler cross 
Dog R13 4 M Neutered Kelpie cross 
Dog R14 3 M Neutered Shar-pei cross 
Dog R15 2 M Neutered Golden retriever 
Dog R16 5 M Neutered Rottweiler 
Dog R17 4 M Entire Brittany spaniel 
Dog R18 5 F Neutered Border collie 
Dog R19 4 F Entire Border collie 
Dog R20 1 F Entire Akita 
Table 8 Results of biochemistry analytes of the dog population chosen as the healthy reference. Highlighted values are outside the commercial laboratory reference intervals. Na, 
sodium; K, potassium; Cl, chloride; ALT, alanine transaminase; AST, aspartate transaminase; ALP, alkaline phosphatase; GGT, γ-glutamyltransferase; Bil, bilirubin; Chol, 
cholesterol; Trig, triglyceride; Creat, Creatinine; TP, total protein; Alb, albumin; Phos, phosphate 
Analyte Na K Cl ALT AST ALP GGT Bil Chol Trig Creatinine Urea TP Alb Glucose Calcium Phos 
 mmol/L mmol/L mmol/L U/L U/L U/L U/L µmol/L mmol/L mmol/L µmol/L mmol/L g/L g/L mmol/L mmol/L mmol/L 
Reference 
interval 139-154 3.4-5.3 99-120 21-142 10-60 20-184 1-8 2-17 3.3-6.9 0.6-1.2 44-132 3.6-10 56-80 24-38 3.6-6.8 2.2-2.8 0.8-2.2 
Table 9 Commercial laboratory reference intervals using an AU480 Chemistry Analyser. Highlighted RI cannot be transferred for use with the COBAS INTEGRA analyser
 Na K Cl ALT AST ALP GGT Bil Chol Trig Creat Urea TP Alb Glucose Calcium Phos 
 mmol/L mmol/L mmol/L U/L U/L U/L U/L µmol/L mmol/L mmol/L µmol/L mmol/L g/L g/L mmol/L mmol/L mmol/L 
Dog R1 152 4.4 115.6 20.8 25.2 17.5 5.3 0.9 5.2 0.9 85 7.8 58 35.2 5.7 2.5 1.4 
Dog R2 154.8 4.3 114.7 52.5 23.3 55 4.8 0.2 6.3 1.0 76 4.3 62.6 37.6 6.6 2.6 0.8 
Dog R3 153.1 4.2 116.8 58.1 30.5 40.5 5.1 0.5 3.8 0.4 79 8.0 54.5 33.4 5.1 2.7 1.9 
Dog R4 155.7 4.2 118.0 22.3 29.9 34.1 5.9 0.5 5.5 1.1 87 6.3 62 37.8 5.8 2.6 0.9 
Dog R5 153.5 4.2 103.4 34.9 40.6 106 4.7 1.3 6.7 1.1 115 8.6 69.9 37.0 5.9 2.6 1.4 
Dog R6 152.6 4.3 111.7 24.3 23.4 59.2 3.5 0.8 9.9 0.5 63 3.7 58.7 39.1 5.3 2.6 1.3 
Dog R7 153.5 4.7 114.1 50.6 22.1 111.9 8.6 1.2 5.0 2.0 139 6.4 60.4 35.1 6.1 2.7 1.2 
Dog R8 153.4 4.1 114.0 42.2 25.9 34.8 5.8 1.6 6.0 0.8 67 5.1 60 37.9 5.5 2.6 1.0 
Dog R9 156.4 4.6 118.7 63.7 33 32.7 6.3 2.8 7.4 1.1 61 5.4 57.4 38.0 5.4 2.6 1.2 
Dog R10 153.4 4.6 113.1 33.4 18.9 28.6 6.7 0.7 8.0 1.1 73 4.5 61.5 39.0 5.3 2.7 1.2 
Dog R11 152.2 4.5 111.1 42.4 50 59.7 7.5 1.3 5.2 0.6 81 4.2 62.6 38.9 5.9 2.6 1.0 
Dog R12 154.4 4.3 117.3 40.4 30 59.8 3.4 0.9 3.7 1.1 121 11.4 55.1 35.1 4.6 2.6 1.3 
Dog R13 154.3 4.2 119.2 37.4 38.4 33.4 4.9 0 4.8 0.3 95 5.1 56.3 33.3 5.3 2.5 0.9 
Dog R14 153.2 4.2 114.2 13.8 20.8 21.8 4.1 0.9 5.0 0.6 105 5.2 58.3 40.0 5.8 2.7 1.0 
Dog R15 152.8 4.7 115.1 24.6 26.3 64.7 5.9 1 8.7 0.7 102 5.8 56.4 37.0 5.2 2.5 1.3 
Dog R16 152.7 4.6 112.9 31.2 34.5 45.9 5.8 0.5 6.1 1.1 82 5.1 58.7 34.8 4.8 2.6 1.3 
Dog R17 153.9 4.1 115.3 30.3 38.2 29.4 5.1 0.3 5.1 0.6 74 4.7 65 34.9 5.9 2.5 1.3 
Dog R18 154.7 4.4 115.9 26.4 28.8 36.3 8.6 1 3.8 0.4 68 4.2 58.5 40.5 5.6 2.6 1.7 
Dog R19 154 4.4 114.6 20 23.2 20.3 4.6 0.7 6.4 0.8 95 6.5 62.8 38.4 6.0 2.7 1.2 
Dog R20 153.7 4.6 115.8 34.4 23.9 17.3 6.4 2 4.0 0.9 102 8.4 59.6 38.6 5.7 2.5 1.2 
Table 10 Signalment of the additional 31 dogs that provided plasma samples for generating de novo reference 
intervals 
  
 Age Sex Neuter status Breed 
Dog R21 4 M Neutered Finnish Lapphund 
Dog R22 7 F Entire Border collie 
Dog R23 1 M Entire Labrador retriever 
Dog R24 1 F Entire Kelpie cross 
Dog R25 2 F Entire Cattle dog 
Dog R26 0.5 F Entire Bull Arab cross 
Dog R27 6 F Entire Staffordshire bull terrier cross 
Dog R28 0.5 F Entire Kelpie cross 
Dog R29 4 M Neutered Staffordshire bull terrier 
Dog R30 0.5 M Neutered Border collie cross 
Dog R31 0.5 F Neutered Kelpie cross 
Dog R32 0.75 F Neutered Maltese cross 
Dog R33 1 M Neutered Labradoodle 
Dog R34 0.5 M Neutered Corgi cross 
Dog R35 4 M Entire Labrador retriever 
Dog R36 1 M Entire Chihuahua cross 
Dog R37 0.5 M Entire Dachshund cross 
Dog R38 0.5 F Entire Corgi cross 
Dog R39 4 M Entire Staffordshire bull terrier cross 
Dog R40 1 M Entire Bull terrier 
Dog R41 3 M Neutered Staffordshire bull terrier 
Dog R42 2 F Neutered Staffordshire bull terrier cross 
Dog R43 3 M Neutered Rottweiler cross 
Dog R44 2 M Neutered Border collie 
Dog R45 adult F Neutered Border collie 
Dog R46 2 M Neutered Border collie 
Dog R47 3 F Neutered Mixed breed 
Dog R48 3 M Neutered Finnish Lapphund 
Dog R49 adult M Entire Rhodesian ridgeback 
Dog R50 2 M Neutered Border collie 
Dog R51 5 M Neutered Doberman 
 Na ALT Bil Chol Trig Alb 
 mmol/L U/L µmol/L mmol/L mmol/L g/L 
Dog R21 152.1 19.1 0.1 4.4 1.6 32.5 
Dog R22 153.7 39 0.5 3.9 0.45 37.8 
Dog R23 150.4 48.3 N/A 6.6 1 35.5 
Dog R24 151 22.8 N/A 5.9 0.72 35.3 
Dog R25 148.3 21.4 N/A 9.1 1.33 33.0 
Dog R26 N/A 29.8 N/A 6.3 0.3 33.8 
Dog R27 149.2 27.3 N/A 6.7 0.49 38.0 
Dog R28 149.9 16.8 N/A 6.4 1.07 34.5 
Dog R29 156.5 N/A N/A 7.9 1.44 37.8 
Dog R30 N/A 20.6 N/A 7.7 N/A 35.4 
Dog R31 N/A 20.5 N/A 8.3 1.39 36.6 
Dog R32 153.5 34.5 N/A 5.5 1.18 36.7 
Dog R33 151.4 73.7 N/A 6.1 0.7 35.8 
Dog R34 151.6 34.7 N/A 6.0 0.59 32.3 
Dog R35 151.5 73.5 N/A 6.0 0.65 38.6 
Dog R36 N/A 27.4 N/A 6.4 0.37 43.0 
Dog R37 N/A 63.8 N/A 5.6 0.99 32.9 
Dog R38 N/A 29.4 N/A N/A N/A 34.9 
Dog R39 N/A 38.7 N/A N/A N/A 37.5 
Dog R40 151.4 38.4 N/A 4.7 0.27 37.8 
Dog R41 152.1 32.2 N/A 5.2 0.34 40.2 
Dog R42 150.2 33.1 N/A 4.7 0.33 37.3 
Dog R43 N/A N/A 0.6 N/A N/A N/A 
Dog R44 N/A N/A 0.8 N/A N/A N/A 
Dog R45 N/A N/A 1 N/A N/A N/A 
Dog R46 N/A N/A 0.4 N/A N/A N/A 
Dog R47 N/A N/A 1 N/A N/A N/A 
Dog R48 N/A N/A 0.4 N/A N/A N/A 
Dog R49 N/A N/A 0.3 N/A N/A N/A 
Dog R50 N/A N/A 0.6 N/A N/A N/A 
Dog R51 N/A N/A 0.4 N/A N/A N/A 
Table 11 Data from a healthy dog population for generating de novo RI. Na, sodium; ALT, alanine transaminase; 








of data N Median SD Min Max 























ALT Nonparametric No 41 - - - - - 14.0 73.7 13.8 to 19.1 0.1 63.7 to 73.7 0.2 
Cholesterol Nonparametric No 40 - - - - - 3.7 9.8 3.7 to 3.9 0.04 8.7 to 9.9 0.2 
Albumin Robust Yes 42 6.9 0.4 6.3 7.8 0.27 31.8 41.9 31.0 to 32.9 0.2 40.8 to 43.1 0.2 







Triglycerides Robust Yes 39 -0.5 0.6 -1.6 0.7 0.69 0.3 2.0 0.2 to 0.3 0.1 1.7 to 2.4 0.4 
Bilirubin Robust Yes 31 0.02 0.5 -0.8 1.4 0.008 0.01 2.1 -0.1 to 0.2 0.1 1.6 to 2.7 0.5 
Table 12 The narrowest CI for the upper and lower reference interval was produced when using the nonparametric method for ALT and cholesterol and the robust method after Box-
Cox transformation for sodium, triglyceride, albumin, and bilirubin. Data for sodium, triglyceride and albumin were confirmed for symmetry (>0.05 indicated no significant deviation from 
symmetry). Bilirubin failed the test for symmetry however visual examination of the histogram found reasonable symmetry. RI generated using Reference Value Advisor version 2.1 
and Microsoft Excel. ALT, alanine transaminase; CI, confidence interval; RI, reference interval; SD, standard deviation; N, number of samples 
 
3.3 Discussion 
RI were successfully transferred or generated de novo for the COBAS INTEGRA biochemistry analyser. A 
limitation of the generated RI was the relatively small number of healthy dogs used for the basis of RI 
calculations. ASVCP guidelines recommend using at least 40 samples from healthy dogs when creating RI, 
however also recognise that fewer samples may be necessary and in such cases recommend to include 90% CI 
of the reference and histograms.(180) The histograms give a visual indication of the variation, presence of 
outliers and whether the data is symmetrical in distribution.  
Most guidelines suggest that the width of the 90% CI of the upper and lower limit should not exceed 0.2 times the 
width of the RI.(180) In this study, the CI is more than 0.2 times the width of the RI for the lower limit of sodium, 
the upper limit of bilirubin and the upper limit of triglyceride. These three CI were examined individually, the 
results being 148-150 mmol/L (lower limit of sodium), 1.7-2.4 mmol/L (upper limit of triglyceride) and 1.6-2.7 
µmol/L (upper limit of bilirubin). The width of these confidence intervals was considered to be reasonably narrow 
and were likely adequate for confirming the health status of dogs in the current equivalence study. If the COBAS 
INTEGRA were to enter routine clinical use, further samples should be added to the reference data to narrow the 
CI further and increase the accuracy of the RI for differentiating ill dogs.  
Other limitations of the current RI were the predominance of medium- to large-breed dogs and young dogs in the 
reference population. Studies in dogs have found the existence of breed-related, age-related and sex-related 
(including neutering) differences in RI.(187) For example, a study in 32 healthy Bernese Mountain dogs found 
that RI for ALP, GGT, amylase, cholesterol and bilirubin could not be transferred from the general dog 
population.(188) When specific RI were generated for Bernese Mountain dogs, the limits were higher for ALP, 
GGT, amylase and cholesterol, but lower for total bilirubin. Small-breed dogs were also suggested to have 
different RI for some analytes compared to the general population, including significantly lower plasma creatinine 
concentrations and higher albumin concentrations.(189) These RI differences were unlikely to impact on our 
intended use of confirming the health status of dogs enrolling in the second phase of the study. If the COBAS 
INTEGRA were to enter clinical use, a wider selection of dog sizes, breeds and ages should be prospectively 
recruited to better reflect the general population.  
The youngest dogs in the reference population were 6 months old, thus were not fully mature. Puppies are known 
to have significantly higher serum ALP activity, and calcium and phosphorus concentrations, as these are altered 
by growth.(190) The decision to include dogs from 6 months of age was based on the relative stability of the 
analytes requiring de novo RI generation (sodium, ALT, bilirubin, cholesterol, triglyceride, and albumin).  
Specifically, no age-related effect was seen in ALT activity, or cholesterol and albumin concentrations in one 
study of 34 Beagles and 44 Labradors.(191) Another study comparing beagles between the ages of 6 to 12 
months found no significant variation with age in plasma albumin, bilirubin, cholesterol and sodium 
concentrations.(192) The same study did, however, find a trend of increasing triglyceride concentrations from 6 
months to 12 months of age, however the difference was not statistically significant. Another study that examined 
changes in cholesterol and triglycerides reported contrary findings, with a decreasing trend in plasma triglyceride 
concentration between 6 months and 12 months of age in 24 Labradors and 25 miniature schnauzers.(193) A 
decreasing trend in cholesterol and triglycerides after 6 months of age was also reported in a prospective study in 
25 beagles.(194) The variable findings between studies on age-related effects on blood cholesterol and 
triglyceride concentrations may be due to the confounding effects of diet, breed differences and time of neutering 
(that removes the possible hormonal effect on lipase activity).(193, 194) The same prospective study of 25 
beagles by Wolford and others (1988) found that bilirubin and ALT were stable between 3 months and 12 months 
of age.(194) Similarly, the study found serum sodium concentrations were similar in puppies older than 6 weeks, 
compared to adult dogs.(194) Thus, the measurements from dogs from 6 months of age were kept for calculation 
of the RI for sodium, ALT, bilirubin, cholesterol, triglyceride, and albumin. The exact impact of the breed and ages 
in this current reference study was not further assessed.  
The Tukey test flagged one potential outlier in the bilirubin dataset.(180) The outlier measurement was 2.8 
µmol/L from Dog R9, a value which would be considered normal based on clinical experience and other general 
RI for bilirubin.(195) Dog R9 was a 7-year-old female neutered standard poodle with normal liver enzyme 
activities. As there was no reason to suspect the dog was ill or that it was an erroneous reading, the outlier was 
retained as per the ASVCP guidelines.(180) The remaining 30 dogs had bilirubin measurements between 0.1- 2 
mmol/L. 
3.4 Conclusion 
The COBAS INTEGRA had RI for 11 biochemical analytes transferred from an external commercial laboratory 
after validation. De novo RI were generated for 6 analytes (sodium, ALT, bilirubin, cholesterol, triglyceride, and 
albumin). Establishment of RI allowed the use of the COBAS INTEGRA analyser for screening healthy dogs prior 
to enrolment for the ACTH stimulation study. 
 
  
4. Comparison of a compounded adrenocorticotropic hormone for 
assessment of adrenal function 
The second objective of this thesis was to establish the equivalency of the cortisol response to compounded 
Bova ACTH (tetracosactide, Bova Aus, Caringbah, NSW, Australia) in heathy dogs, against responses to a 
commercial synthetic ACTH preparation (Synacthen, Mallinckrodt Pharmaceuticals, Staines-upon-Thames, 
Surrey, UK).  If equivalence was confirmed, Bova ACTH preparation could be preliminarily used for the diagnosis 
and management of canine adrenal diseases by Australian veterinarians, especially when there are commercial 
shortages of Synacthen.  
The hypothesis was that Bova ACTH would produce equivalent cortisol concentrations 1 hour after ACTH 
administration compared to Synacthen in healthy dogs.  
4.1 Methodology 
Ethics approval was obtained from the Murdoch University Animal Ethics Committee (Permit No. R2797/15) and 
20 dogs were subsequently enrolled with owner consent. All dogs belonged to staff or students of Murdoch 
University. Details of the dogs’ health and prior diseases, and any current drug administration were obtained from 
the owners. A physical examination was undertaken and venous blood from the jugular, cephalic or saphenous 
vein was sampled using 3 mL or 5 mL syringes and 22 or 23 G 1-inch needles. After removal of the needle, the 
blood was ejected from the syringe into a 1 mL EDTA tube and a 4 mL serum tube. The EDTA sample was 
submitted for a haematology profile (Sysmex XT 2000i) and the serum sample was used for routine biochemical 
analysis using a COBAS INTEGRA 400 plus analyser. The ALP activity in 9 dogs, bilirubin concentration in 1 
dog, and sodium and potassium concentrations in 1 dog were measured using a Beckman Coulter AU 480 and 
compared to the laboratory reference interval. A voided urine sample was collected, and urine specific gravity 
and urine dipstick performed.  
Red cell analytes measured included haemoglobin (Hb), haematocrit (Hct), red blood cell count (RBC), mean cell 
haemoglobin concentration (MCHC), mean cell haemoglobin (MCH), mean corpuscular volume (MCV), 
reticulocyte count (Retic abs), reticulocyte percentage (Retic) and nucleated red cells (NRBC). White cell 
analytes measured included automated total white blood cell count and a 100-cell manual differentiation count 
(for neutrophils, bands, lymphocytes, monocytes, eosinophils and basophils). An automated platelet count was 
measured and if less than 200 x 109/L a manual platelet count was performed. A manual blood smear to evaluate 
the red blood cell, white blood cell, and platelet morphology was also performed. Serum biochemistry analytes 
measured included alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP) and 
γ-glutamyltransferase (GGT) activities; and concentrations of creatinine, urea, bilirubin, cholesterol, triglyceride, 
glucose, total protein, albumin, total calcium, potassium, chloride, sodium and phosphate. Urinalysis included 
urine specific gravity (measured with a hand-held refractometer) and urine dipstick Multistix Siemens (München, 
Germany) which semi-quantitatively detected glucose, ketone, bilirubin, blood, pH, and protein. 
Exclusion criteria included pre-existing disease or injury and clinically significant abnormalities identified on 
physical examination, blood or urine tests. Dogs were also excluded if they were receiving medication other than 
parasite prevention (including pyrantel embonate, oxantel embonate, praziquantel or afoxolaner) in the month 
before the study commencement or had an injectable glucocorticoid administered within 2 months of study 
commencement. Dogs did not receive any medication during the two periods of testing. 
The study was a crossover design with a balanced treatment allocation determined by selection of a card from an 
envelope. Ten cards determined that dogs were administered Bova ACTH first, and 10 cards determined that 
dogs were administered Synacthen first. The first dog to be tested on a given day was assigned a card. 
Subsequent dogs being tested on the same day were allotted the same treatment order as the first card drawn to 
allow full use of each opened 1 ml vial of ACTH. If the vial contents were exhausted and more dogs were 
available for testing, a second card was drawn, and that sequence followed. The number of dogs being tested on 
any day varied between 1 to 4 depending on owner availability. Dogs were fasted from midnight the night before 
testing was undertaken to reduce the likelihood of postprandial lipaemia, which potentially interferes with the 
cortisol assay.  
All ACTH preparations were stored at 4oC until immediately prior to injection. Vials of Synacthen and sealed 
syringes of Bova ACTH were opened on the day of testing and any remaining ACTH was discarded. Batch 
numbers were noted for all ACTH preparations used.  
The ACTH stimulation test procedure consisted of the following steps: 
1. A dog was assigned Synacthen or Bova ACTH on Day 1 according to the card drawn out of the envelope as 
described above. 
a) 4-5 mL of blood was collected by jugular or saphenous venepuncture with a 22G 1-inch needle 
and 5 mL syringe. After removal of the needle the blood was ejected from the syringe into one or 
more 4.0 mL serum tubes (BD Vacutainer® serum tube with silica clot activator, Franklin Lakes, 
New Jersey, USA). This sample was labelled t=0 
b) 5 µg/kg of the first ACTH preparation to be tested (Bova or Synacthen) was administered IV with 
a 23 G 1-inch needle via the cephalic or saphenous vein. The syringe plunger was drawn back 
before injection in order to visualise blood in the syringe and to ensure that the needle was in the 
vein 
c) The blood sample collected in a) was left to clot at room temperature for 30-120 minutes  
d) Once the blood was clotted, the collection tubes were centrifuged at 1358 X g for 10 minutes at 
4oC 
e) The supernatant (serum) was aliquoted into two plain polypropylene tubes and labelled as t=0 
f) The serum samples were then frozen at -80oC  
2. A second blood sample was collected 1 hour after the administration of ACTH and processed as described 
in Steps c-f. This sample was labelled t=1. 
3. On the following day (Day 2) the ACTH stimulation test (as described in steps a-f) was repeated using the 
alternative ACTH preparation. The ACTH was injected into the same or different vein as compared to 24 
hours prior. The timing of the second ACTH stimulation test was 24-25 hours after the first stimulation test. 
Once samples had been collected from all 20 dogs, one aliquot of each sample was shipped frozen on dry ice to 
a reference laboratory (Vetnostics, Macquarie Park, NSW, Australia) for measurement of cortisol using the 
ADVIA Centaur® chemiluminescent assay (Bayer Diagnostics, Leverkusen, Germany). The chemiluminescent 
assay had precision testing performed on the morning of the cortisol assay as well as regular quality control 
testing, including participation in the European Society of Veterinary Endocrinology External Quality Assessment 
Scheme.(196) The cortisol assay was performed in duplicate for each sample. The duplicate cortisol 
measurements were then averaged prior to further data analysis. Cortisol concentrations that were below the 
detectable limit of the assay (below 13.8 nmol/L) were converted to 13.7 nmol/L for data analysis. Intra-assay 
coefficient of variation was calculated on the day of the assay. The RI of cortisol concentrations used by 
Vetnostics after ACTH stimulation was 180-380 nmol/L.  
4.2 Statistical methods 
Dogs that had significantly abnormal ACTH stimulation results were excluded from further statistical analysis. 
Descriptive statistics were used to summarise the basal (t=0) cortisol concentrations, including mean, standard 
deviation (SD) and range. The t=0 cortisol concentration was compared between each day of testing to verify that 
the starting concentration was not different for each compound. Normality of the cortisol concentration was 
verified by failure to reject the null hypothesis of normality using the Shapiro-Wilk statistic, and through 
visualisation of Q-Q plots. A paired t-test was used with p ≤0.05 considered significant. SAS v9.4 (SAS Institute, 
Cary, North Carolina, USA ) was used for analysis.  
The post-stimulation (t=1) cortisol concentration was the response of interest. For the purposes of the study, the 
hypothesis that the cortisol response to Bova ACTH is equivalent to that of Synacthen would be accepted if the 
95% CI, calculated as the mean ± 1.96 SD/√𝑛,  of the mean cortisol ratio after Bova ACTH compared to 
Synacthen (Bova/Synacthen) fell within the equivalence range of 0.8-1.25 (Microsoft Excel, v1810, Microsoft, 
Redmond, Washington, USA).  
Bland-Altman plots (MedCalc Statistical Software version 18, Ostend, Belgium; http://www.medcalc.org) were 
used for visual comparison between cortisol concentrations at t=1 in each dog.(97) One graph plotted the cortisol 
difference (Bova ACTH minus Synacthen) against the mean cortisol for each dog. The bias (mean difference 
between the Bova ACTH and Synacthen) and the 95% limits of agreement (mean difference ± 1.96 SD, 
approximating a 95% prediction interval for the difference) were calculated. The 95% CI of the bias and the limits 
of agreement were calculated. A second Bland-Altman graph plotted the cortisol ratio (Bova ACTH/Synacthen) 
against the mean cortisol for each dog. The bias, 95% limits of agreement and 95% CI of these estimates were 
calculated. Equivalence of the responses to the two ACTH preparations would be further supported if the 95% CI 
of the limits of agreement on Bland-Altman analysis of the ratio were within 0.8-1.25. Bland-Altman data were 
then stratified and colour-coded (based on Bova batch number, date of testing and the order of ACTH 
preparation used), in order to highlight any associated bias.  
Cortisol concentrations were also tested using Passing-Bablok regression analysis (MedCalc Statistical Software 
version 18, Ostend, Belgium; http://www.medcalc.org ) with estimates for the intercept and slope of the linear 
regression line reported with 95% CI. The p value for the cusum test for linearity was also reported. Agreement 
would result in an intercept of 0 and a slope of 1. Intercepts significantly different from 0 indicate a systematic 
bias. Slopes significantly different from 1 indicate a proportional bias.  
4.3 Results 
4.3.1 Enrolled dogs 
Twenty dogs were enrolled in the study. All 20 dogs successfully completed the ACTH stimulation testing with no 
adverse reaction to either preparation of ACTH. 
The median age was 4 years (range 1-7) and median weight was 21.9 kg (range 7.7-42.5). There were 4 entire 
dogs (3 female and 1 male) and 16 neutered dogs (5 females and 11 males). There were 5 mixed breeds, 4 French 
bulldogs, 2 German shepherds, 2 Australian shepherds, 2 Labradors, and 1 each of Cavalier King Charles spaniel, 
boxer, cocker spaniel, American Staffordshire terrier, and giant schnauzer. The ACTH stimulation tests were 
performed between the hours of 8am and 4pm between the 16/12/2017 and 14/4/2018 on 7 separate occasions. 
Three different batch numbers were recorded for Synacthen and 5 different batches were recorded for Bova (Table 
13). The initial beyond-use-date was 3 months for the Bova preparation, however this decreased to 3 days after 1st 
February 2018 based on the manufacturer’s recommendation. This alteration was only a change in labelling and 
there was no change in the compounding or preparation of ACTH. Six dogs were tested prior to February 2018 
using the Bova ACTH within the 3-month expiry and the remaining 14 dogs received Bova ACTH within the 3-day 
expiry.  
4.3.2 Screening test results 
Haematology, serum biochemistry analysis and urinalysis were performed in the 20 enrolled dogs and results are 
presented in Table 13-16. The few parameters outside the reference intervals were considered spurious and 
clinically insigificant. 
  
























Dog 1 4 M Neutered Labrador 29.2 5/9 0.58 17/12/17 C17007 16/12/17 474484 
Dog 2 1 F Neutered Mixed breed 11.5 4/9 0.23 17/12/17 C17007 16/12/17 474484 
Dog 3 5 M Neutered Labrador 42.5 7.5/9 0.85 2/03/18 C17055 1/03/18 474484 
Dog 4 4 F Neutered Mixed breed 7.7 4/9 0.15 17/12/17 C17007 16/12/17 474484 
Dog 5 5 F Neutered French bulldog 10.1 5/9 0.2 27/01/18 C17007 28/01/18 474484 
Dog 6 6 F Entire French bulldog 10.9 5/9 0.22 27/01/18 C17007 28/01/18 474484 
Dog 7 4 M Entire French bulldog 13.9 6/9 0.28 14/04/18 C17055 15/04/18 483204 
Dog 8 7 M Neutered Cavalier King Charles 11.3 7/9 0.23 27/01/18 C17007 28/01/18 474484 
Dog 9 7 M Neutered Mixed breed 27 5/9 0.54 29/03/18 C17055 28/03/18 483204 
Dog 10 7 M Neutered Mixed breed 11.1 8/9 0.22 14/04/18 C17055 15/04/18 493530 
Dog 11 3 M Neutered Australian shepherd 22.5 3/9 0.45 1/03/18 C17055 2/03/18 487366 
Dog 12 4 F Neutered Australian shepherd 21.9 7/9 0.44 1/03/18 C17055 2/03/18 487366 
Dog 13 6 M Neutered Giant schnauzer 38.1 4/9 0.76 28/03/18 C17055 27/03/18 483204 
Dog 14 2 M Neutered German shepherd 28.8 4/9 0.58 19/04/18 C17061 20/04/18 494519 
Dog 15 2 M Neutered Mixed breed 19.9 4/9 0.4 13/04/18 C17055 12/04/18 493060 
Dog 16 3 F Entire French bulldog 21.9 6/9 0.44 14/04/18 C17055 15/04/18 483204 
Dog 17 2 F Entire Boxer 25 5/9 0.5 13/04/18 C17055 12/04/18 493060 
Dog 18 2 M Neutered Cocker spaniel 21 6/9 0.42 13/04/18 C17055 12/04/18 493060 
Dog 19 1 M Neutered American Staffordshire terrier 30.4 6/9 0.61 13/04/18 C17055 12/04/18 493060 
Dog 20 2 F Neutered German shepherd 30.8 5/9 0.62 14/04/18 C17055 15/04/18 493530 
Table 13 Characteristics of the 20 dogs tested and the dates of testing and ACTH preparations used for ACTH stimulation in each subject
 Hb Hct RBC MCHC MCH MCV Retics Retics WBC Neut Bands Lymph Mono Eos Baso NRBC Plt 
RI 120-180 0.37-0.55 5.5-8.5 320- 360 20-25 60- 77  < 95 6.0- 17.0 3.0- 11.5 0 - 0.30 1.0-4.8 0.15- 1.35 0.1- 1.25   200-900 




Dog 1 145 0.4 5.6 355 26 73 0.32 17.9 12.5 8.12 0 3.25 0.5 0.62 0 0 250 
Dog 2 186 0.52 7.8 358 24 67 0.77 60.1 12.5 8.75 0 2.62 0.5 0.62 0 0 251 
Dog 3 170 0.49 7.4 344 23 67 - - 11.1 7.22 0 2.33 0.44 1 0.11 0 132 
Dog 4 157 0.45 6.4 349 25 70 - - 6.6 4.49 0 1.78 0.13 0.2 0 0 91 
Dog 5 181 0.52 7.4 344 25 71 - - 5.4 4 0 1.03 0.32 0.05 0 0 154 
Dog 6 186 0.54 7.6 345 25 71 - - 5.6 4.09 0 0.9 0.39 0.22 0 0 304 
Dog 7 188 0.53 7.9 350 24 68 - - 6.8 5.24 0 0.88 0.54 0.14 0 0 232 
Dog 8 163 0.47 6.7 339 24 71 - - 7.2 4.82 0 1.8 0.22 0.36 0 0 102 
Dog 9 156 0.45 6.5 348 24 69 - - 10.2 7.75 0 1.22 0.31 0.92 0 0 362 
Dog 10 230 0.63 9.2 365 25 68 0.96 88.3 8.8 6.95 0 1.41 0.35 0.09 0 0 270 
Dog 11 170 0.48 6.7 353 26 73 0.53 35.5 8.2 4.59 0 2.62 0.33 0.66 0 0 373 
Dog 12 157 0.44 6.5 354 24 68 0.26 16.9 5.5 3.52 0 1.49 0.28 0.22 0 0 295 
Dog 13 140 0.4 6 342 24 69 - - 5.9 3.78 0 1.65 0.3 0.18 0 0 76 
Dog 14 158 0.46 7 336 23 68 - - 4.9 3.18 0 1.42 0.1 0.2 0 0 122 
Dog 15 208 0.56 8.2 371 25 66 - - 6.9 4.14 0 1.93 0.21 0.55 0.07 0 55 
Dog 16 199 0.57 7.8 345 26 74 - - 10.1 7.47 0 1.41 0.3 0.91 0 0 234 
Dog 17 182 0.51 7.7 357 24 63 - - 10.1 6.57 0 2.83 0.2 0.5 0 0 263 
Dog 18 153 0.43 6.4 356 24 66 - - 10 7.5 0 2 0.3 0.2 0 0 234 
Dog 19 160 0.49 6.8 322 24 74 - - 7.1 5.75 0 0.71 0.21 0.43 0 0 157 
Dog 20 186 0.54 7.6 342 24 71 - - 8.9 5.96 0 1.78 0.53 0.62 0 0 105 
Table 14 Haematology results from the 20 dogs in the study, highlighted values are outside laboratory reference interval (RI). Hb, haemoglobin; Hct, haematocrit; RBC, red 
blood cell count; MCHC, mean corpuscular haemoglobin concentration; MCH, mean cell haemoglobin; MCV, mean corpuscular volume; Retics, reticulocytes;; WBC, white 
blood cell count; Neut, neutrophils, Lymph, lymphocytes; Mono, monocytes; Eos, eosinophils; Baso, basophil;, NRBC, nucleated red blood cells; Plt, platelets 
 
Table 15 Haematology results including morphology of red cells, white cells and platelets
  Red blood cell morphology White blood cell morphology Platelets 
Haemolysis Lipaemia 
Dog 1 normal normal adequate - - 
Dog 2 normal normal adequate - - 
Dog 3 
1+ anisocytosis, occasional 
polychromatophil 
normal 3+ clumps 
- - 
Dog 4 
1+ anisocytosis, occasional 
polychromatophil 
normal adequate, 2+ clumps 
- - 
Dog 5 normal normal adequate, rare clumps - - 
Dog 6 normal normal adequate - - 
Dog 7 normal occasional reactive lymphocyte adequate - - 
Dog 8 normal normal adequate, occasional clumps - - 
Dog 9 normal normal adequate - - 
Dog 10 normal normal adequate - - 
Dog 11 normal normal adequate, rare shift platelets - - 
Dog 12 normal normal adequate - - 
Dog 13 normal normal adequate, 3+ clumps - - 
Dog 14 normal normal adequate, few clump - - 
Dog 15 normal normal adequate 2+ clumps 1+, clot 2+ - 
Dog 16 normal normal adequate - - 
Dog 17 normal normal adequate - - 
Dog 18 normal normal adequate - - 
Dog 19 normal normal adequate, 2+ clumps - - 
Dog 20 normal normal adequate, 1+ clumps - - 
 




3.4-5.3 Na: K 99-120 14-73.7 10-60 20-184 1-8 
0.01-
2.1 
3.7-9.8 0.3-2.0 44-132 3.6-10 56-80 
31.8-
41.9 
3.6-6.8 2.2-2.8 0.8-2.2 
Unit mmol/L mmol/L  mmol/L U/L U/L U/L U/L µmol/L mmol/L mmol/L µmol/L mmol/L g/L g/L mmol/L mmol/L mmol/L 
Dog 1 151.1 4.5 33.6 112.5 16.2 19.4 35.0 4.7 0.6 5.6 0.6 72.0 5.3 57.4 34.8 5.1 2.6 1.6 
Dog 2 153.2 5.0 30.6 116.8 35.8 47.6 34.0 3.7 <2 6.0 1.0 91.0 8.8 53.5 37.9 4.1 2.7 2.1 
Dog 3 156.5 4.8 32.6 116.1 43.5 35.8 38.0 2.2 1.3 4.3 0.6 108.0 5.4 62.7 39.3 5.2 2.6 1.5 
Dog 4 153.4 4.1 37.4 116.4 65.8 34.3 58.0 3.8 0.8 3.0 0.3 128.0 6.0 55.2 39.6 6.8 2.7 1.2 
Dog 5 152.4 4.9 31.1 111.6 73.9 25.0 18.0 5.1 1.5 5.2 0.5 82.0 6.6 56.4 39.5 6.1 2.6 1.7 
Dog 6 151.8 4.9 31.0 111.9 29.9 20.2 24.0 4.0 0.9 4.8 0.5 76.0 5.6 59.4 39.6 5.3 2.6 1.9 
Dog 7 154.0 4.7 32.8 114.2 31.3 30.0 13.0 5.4 0.7 3.6 0.3 82.0 4.9 55.1 39.9 5.5 2.5 1.5 
Dog 8 152.9 4.8 31.9 110.1 17.4 14.0 90.0 5.0 0.3 9.3 0.8 40.0 3.6 56.3 39.8 5.3 2.6 1.6 
Dog 9 154.2 4.8 32.1 112.9 20.9 21.8 60.0 6.5 0.3 7.7 0.5 58.0 5.0 62.4 36.5 5.5 2.5 1.3 
Dog 10 156.5 4.7 33.3 117.4 24.1 25.2 30.6 7.4 1.4 8.3 0.5 73.0 5.8 62.3 43.7 6.6 2.7 1.6 
Dog 11 152.0 4.7 32.3 118.0 40.8 28.7 106.4 6.3 0.6 6.3 0.5 82.0 3.4 55.0 33.1 5.9 2.8 1.2 
Dog 12 151.2 4.1 36.9 115.8 71.6 35.4 123.1 7.1 0.8 8.7 0.6 61.0 3.6 52.0 32.5 5.6 2.6 1.2 
Dog 13 151.0 5.0 30.2 114.5 33.9 27.6 88.0 11.7 0.6 7.2 0.5 70.0 7.5 58.6 41.0 5.4 2.7 1.3 
Dog 14 153.7 4.6 33.4 116.4 30.2 32.3 15.7 7.2 1.0 4.3 0.4 95.0 6.0 63.2 35.6 5.8 2.4 1.9 
Dog 15 152.8 5.0 30.6 113.7 30.9 30.5 14.8 2.4 2.2 5.1 0.4 91.0 4.6 58.4 39.9 6.1 2.7 1.5 
Dog 16 140.0 4.9 28.6 116.7 35.4 19.6 27.1 5.1 0.3 7.6 1.2 92.0 3.6 66.6 39.8 5.9 2.7 1.9 
Dog 17 154.5 4.2 36.8 115.2 61.4 36.6 49.5 5.9 1.7 7.7 0.4 80.0 4.9 54.2 38.8 6.1 2.6 1.5 
Dog 18 155.0 4.2 36.9 113.5 79.8 43.2 36.9 9.4 0.9 6.5 0.3 52.0 7.1 56.9 40.4 5.4 2.8 1.8 
Dog 19 152.6 4.7 32.5 113.0 25.7 23.8 31.8 5.1 1.1 6.5 0.4 68.0 2.5 56.6 37.8 6.1 2.6 2.0 
Dog 20 152.5 4.9 31.1 113.9 50.3 27.0 32.8 5.3 0.4 6.3 0.9 87.0 8.3 56.0 35.6 5.3 2.6 2.1 
Table 16 Biochemistry results of enrolled dogs, highlighted values are outside laboratory reference interval (RI). Na, sodium; K, potassium; Cl, chloride; Na:K, sodium potassium 
ratio; ALT, alanine transaminase; AST, aspartate transaminase; ALP, alkaline phosphatase; GGT, γ-glutamyltransferase; Bil, bilirubin; Chol, cholesterol; Trig, triglyceride; Creat, 





pH Protein Glucose Ketones Blood Bilirubin 
Dog 1 1.042 6 negative negative negative negative 1+ 
Dog 2 1.032 6.5 negative negative negative negative negative 
Dog 3 1.028 8.5 1+ negative negative negative 1+ 
Dog 4 1.026 6.5 negative negative negative negative 1+ 
Dog 5 1.049 6.5 trace negative negative negative negative 
Dog 6 1.047 6.5 trace negative negative negative negative 
Dog 7 1.047 7 1+ negative negative negative 1+ 
Dog 8 1.050 7.5 negative negative negative negative 1+ 
Dog 9 1.030 7 negative negative negative negative 1+ 
Dog 10 1.060 6.5 trace negative negative negative 1+ 
Dog 11 1.022 6 negative negative negative negative 1+ 
Dog 12 1.027 5 negative negative negative negative 1+ 
Dog 13 1.033 5 negative negative negative negative negative 
Dog 14 1.033 5 negative negative negative negative negative 
Dog 15 1.025 6 negative negative negative negative 1+ 
Dog 16 1.023 6 negative negative negative 4+ * negative 
Dog 17 1.030 6.5 trace negative negative negative 1+ 
Dog 18 1.043 6.5 trace negative negative negative 1+ 
Dog 19 1.046 8.5 1+ negative negative negative negative 
Dog 20 1.044 6.5 trace negative negative negative 1+ 
Table 17 Urinalysis results. * urine collected when in proestrus or oestrus 
4.3.3 Cortisol assay 
The screening tests were all performed prior to enrolment. All serum samples were later assayed for cortisol on 
16/8/2018 after samples had been stored at -80oC for 4-8 months. On the day of the batch cortisol assay, intra-
assay coefficients of variation (CV) using two different cortisol concentrations were 3-3.4% (Table 18). General 
precision data for intra-assay and inter-assay CV from previous runs were 2.89-3.82% and 1.86-5.45% 
respectively (Table 19).(197) The CV values generated by the laboratory were similar to the published precision 







1 63.9 465.1 
2 59.9 494.3 
3 61.4 456.1 
4 60.9 463.7 
5 59.8 446.4 
6 58.2 469.7 
7 60.9 479.5 
8 57 486.2 
9 57.7 466.7 
10 60.8 471.9 
Mean 60.05 469.96 
Standard deviation 2.03 14.03 
Coefficient of variation 3.4% 3.0% 
Table 18 Precision data for ADVIA Centaur cortisol assay on the day of the batch assay for the study 
 
Mean (nmol/L) Intra-assay CV (%) Inter-assay CV (%) Total % CV 
107.05 3.69 5.45 6.58 
155.33 3.09 3.83 4.92 
390.95 2.89 3.07 4.22 
759.55 3.82 1.86 4.25 
1024.97 2.98 3.99 4.98 
Table 19 General precision data for ADVIA Centaur cortisol assay 
 
Mean (nmol/L) Intra-assay CV (%) Inter-assay CV (%) 
76.2 3.7 6 
157 3.3 5.3 
614.7 2.9 4.5 
944.7 3.4 4.4 
1393.6 4.2 4.9 
Table 20 Precision data for ADVIA Centaur cortisol assay published by the manufacturer 
4.3.4 Cortisol concentrations 
Two dogs (Dog 9 and Dog 11) had cortisol concentrations markedly outside the RI after both ACTH stimulations 
and they were excluded from statistical analysis. Dog 9, a 7-year-old, male neutered, mixed breed had high 
cortisol concentrations after ACTH stimulation, suggestive of hyperadrenocorticism. Dog 11, a 3-year-old, male 
neutered Australian shepherd had very low cortisol concentrations and was diagnosed with hypoadrenocorticism. 
Dog 9 had received Bova ACTH first, while Dog 11 had received Synacthen first. Dog 9 later underwent a low-
dose dexamethasone suppression test on 19/11/2018 (8 months after ACTH stimulation), which revealed normal 
suppression of serum cortisol concentration (24 nmol/L at t=0, and <14 nmol/L at t=4 and t=8). 
Of the remaining 18 dogs, 14 dogs had cortisol concentrations within laboratory RI after ACTH stimulation testing 
(Table 21). Four dogs (Dog 7, 10, 16 and 20) had cortisol concentrations after ACTH stimulation that were slightly 
outside of the laboratory RI of 180-380 nmol/L but were still considered to have normal adrenal function.  
The 18 dogs that were considered to have normal adrenal function were included in statistical analysis of 
agreement between cortisol concentrations after ACTH stimulation as per the original study criteria. Nine dogs 
received Bova ACTH first, whilst the other 9 received Synacthen first. The mean t=0 cortisol concentration for the 
18 dogs prior to Bova ACTH was 35.4 nmol/L (SD 20.7, range 14.4-102.8), and mean cortisol concentration prior 
to Synacthen was 45.8 nmol/L (SD 67.0, range 13.7-316.2). The cortisol concentrations at t=0 were not 
significantly different  (p=0.4121, paired t-test) between the first and second day of testing. Two dogs (Dog 10 
and 20) had basal cortisol concentrations that were much higher on Day 1 (assigned Synacthen) compared to 
Day 2 (assigned Bova ACTH).  
The mean t=1 cortisol for the 18 dogs after Bova ACTH was 269.4 nmol/L (SD 70.2, range 114.6-387.3). After 
Synacthen stimulation, mean t=1 cortisol concentration was 267.3 nmol/L (SD 70.3, range 125.1-388.0). Using 
data from the same 18 dogs, ratios of cortisol concentration (Bova/Synacthen) at t=1 were calculated, with the 
mean of the ratios determined to be 1.01 (SD 0.075). The 95% CI of the cortisol ratio was 0.98-1.04, which falls 
within the pre-determined equivalence range of 0.80-1.25. 
Bland-Altman analysis plotted t=1 cortisol concentration after Bova ACTH and Synacthen, with the mean on the 
x-axis and the difference (Bova minus Synacthen) on the y-axis (Figure 6). There was homoscedastic distribution 
of the Bland-Altman plot. The calculated bias of the difference was 2.1 nmol/L (95% CI -7.4 to 11.6) and 95% 
limits of agreement were -35.3 nmol/L (95% CI -51.9 to -18.8) and 39.5 nmol/L (95% CI 22.9 to 56.0). In addition, 
a second Bland-Altman graph plotted the mean on the x-axis against the ratio of cortisol concentration 
(Bova/Synacthen) on the y-axis (Figure 7). The calculated bias for the ratio was 1.01 (95% CI 0.97-1.05) and 
95% limits of agreement were 0.87 (95% CI 0.81-0.93) and 1.17 (95% CI 1.09-1.25).  
When the results of the Bland-Altman were stratified based on Bova batch number (Figure 8), date of testing 
(Figure 9) and order of ACTH preparation used (Figure 10), no pattern was discernible on visual assessment. 
The scattered distribution suggests absence of any bias from different batches, the date of testing or the order of 
testing.  
  












Mean of first 
and second 
measurements 
Dog 1 Bova 24.7 23.5 24.1 292.9 309.9 301.4 
Dog 1 Synacthen 22.4 24 23.2 310.8 330.4 320.6 
Dog 2 Bova 23.3 25.3 24.3 303 291.4 297.2 
Dog 2 Synacthen <13.8 <13.8 13.7* 263.9 265.6 264.75 
Dog 3 Bova 51.2 51.9 51.6 269.5 276.7 273.1 
Dog 3 Synacthen 48.9 49.7 49.3 276.8 241.3 259.05 
Dog 4 Bova 36.1 35.2 35.7 322.7 304.9 313.8 
Dog 4 Synacthen 44.5 46.1 45.3 321.4 336.2 328.8 
Dog 5 Bova 19.6 18.7 19.15 211.8 211.4 211.6 
Dog 5 Synacthen 17.2 15.2 16.2 206.6 197 201.8 
Dog 6 Bova 27.2 29.9 28.55 237.1 224.1 230.6 
Dog 6 Synacthen 14.4 13.7 14.05 208.8 209.7 209.3 
Dog 7 Bova 13.8 15 14.4 167.7 172.7 170.2** 
Dog 7 Synacthen 17.6 18.1 17.9 157.2 142.9 150.1** 
Dog 8 Bova 50.9 48.7 49.8 343.2 352.1 347.7 
Dog 8 Synacthen 30.6 29.4 30 316.8 310.4 313.6 
Dog 9 Bova 46.7 40.3 43.5 461.3 514 487.7*** 
Dog 9 Synacthen 21.8 23.4 22.6 504.4 441.9 473.2*** 
Dog 10 Bova 105.9 99.6 102.8 381.4 370.6 376.0 
Dog 10 Synacthen 304.8 327.6 316.2 364.3 401.7 383.0*** 
Dog 11 Bova <13.8 <13.8 13.7* 15.5 14.7 15.1** 
Dog 11 Synacthen <13.8 <13.8 13.7* 16.9 15.8 16.35** 
Dog 12 Bova 22 22.9 22.5 248 236.7 242.35 
Dog 12 Synacthen 22.1 22.3 22.2 253.2 245.5 249.35 
Dog 13 Bova 34.3 35.1 34.7 195.1 197.7 196.4 
Dog 13 Synacthen 27.6 28.8 28.2 205.2 203.3 204.3 
Dog 14 Bova 23.6 19.7 21.7 305.4 321.6 313.5 
Dog 14 Synacthen 27.6 31.6 29.6 282.3 284.1 283.2 
Dog 15 Bova 29.6 32.7 31.2 310.2 301.3 305.8 
Dog 15 Synacthen 24.3 23.9 24.1 303.5 322.6 313.1 
Dog 16 Bova 16.7 17.5 17.1 114.6 114.5 114.6** 
Dog 16 Synacthen 28.4 26.4 27.4 127.2 122.9 125.1** 
Dog 17 Bova 38.1 38.2 38.2 206.8 194.7 200.8 
Dog 17 Synacthen 20.6 22.7 21.7 224.4 220.0 222.2 
Dog 18 Bova 34.9 35.3 35.1 278 259.2 268.6 
Dog 18 Synacthen 28.4 28.6 28.5 285.8 299.5 292.7 
Dog 19 Bova 64.3 64.0 64.2 314.9 281.4 298.2 
Dog 19 Synacthen 59.7 56.6 58.2 314.7 291.5 303.1 
Dog 20 Bova 24.8 20.1 22.5 383.5 391.1 387.3*** 
Dog 20 Synacthen 55.8 61.0 58.4 378.9 397.0 388.0*** 
Table 21 Cortisol concentrations before and after ACTH stimulation; serum samples were run in duplicate and 
averaged. Laboratory reference interval after ACTH stimulation was 180-380 nmol/L. * cortisol concentration of 
< 13.8 nmol was converted to 13.7 nmol for further data analysis, ** cortisol concentration below lower 
laboratory reference limit, *** cortisol concentrations above upper laboratory reference limit 
 
Figure 6 Bland Altman graph plotting the mean of cortisol concentrations at t=1 on the x-axis 
against the difference between cortisol concentrations at t=1 (Bova ACTH-Synacthen) on the y-
axis. The bias (solid line) is 2.1 (95% CI -7.4 to 11.6) and 95% limits of agreement (dashed line) 
are -35.3 (95% CI -51.9 to -18.8) and 39.5 (95% CI 22.9 to 56.0) 
Figure 7 Bland Altman graph plotting the mean of cortisol concentrations at t=1 on the x-axis 
against the ratio of cortisol concentrations at t=1 (Bova ACTH/ Synacthen) on the y-axis. The 
bias (solid line) is 1.01 (95% CI 0.97-1.05) and 95% limits of agreement (dashed line) are 0.87 
(95% CI 0.81-0.93) and 1.17 (95% CI 1.09-1.25) 
 
Figure 8 Bland Altman graph plotting the mean of cortisol concentrations at t=1 on the x-axis against 
the ratio of cortisol at t=1 (Bova ACTH/ Synacthen) on the y-axis. Results are differentiated based on 
batch of Bova used: batch 474484 (blue), batch 483204 (red), batch 493530 (green), batch 487366 
(grey), batch 494519 (purple) and batch 493060 (yellow) 
Figure 9 Bland Altman graph plotting the mean of cortisol concentrations at t=1 on the x-axis against 
the ratio of cortisol concentrations at t=1 (Bova ACTH/ Synacthen) on the y-axis. Results are 
differentiated based on date of first ACTH stimulation test: 16/12/17 (yellow), 27/1/18 (light blue), 
1/3/18 (red), 27/3/18 (grey), 12/4/18 (dark blue), 14/4/18 (green), and 19/4/18 (purple) 
  
Figure 10 Bland Altman graph plotting the mean of cortisol concentrations at t=1 on the x-axis against 
the ratio of cortisol concentrations at t=1 (Bova ACTH/ Synacthen) on the y-axis. Results are 
differentiated based on order of testing: Bova ACTH on Day 1 (yellow) or Synacthen on Day 1 (red) 
4.3.5 Passing-Bablok regression analysis 
Passing-Bablok regression analysis did not identify systematic bias between the cortisol concentrations after 
Synacthen and Bova ACTH stimulation, as the 95% CI of the intercept included zero. There was also no 
proportional bias between Synacthen and Bova ACTH (i.e. the 95% CI of the slope included one). The p value 
for the cusum test for linearity was 0.97, indicating no significant deviation from linearity and supports the 
application of a linear regression model for comparison of cortisol concentrations after ACTH stimulation. 
 
Table 22 Results of Passing-Bablok regression analysis. * If CI includes 0 then there is no systematic bias between 
the two comparisons. ** If CI includes 1, then there is no proportional difference between the two comparisons.  
 
Intercept (95% CI)* 10.50 (-48.72 to 36.99) 
Slope (95% CI)** 0.98 (0.87 to 1.18) 
Cusum test for linearity p=0.97 
4.4 Discussion  
The determination of equivalence in the response after the use of Bova ACTH increases options for the treatment 
and diagnosis of HPA disease, especially in instances of commercial shortages of Synacthen or owners with cost 
constraints. The equivalence in the cortisol concentrations and the Bland-Altman visual inspection show that 
Bova ACTH stimulates cortisol concentrations that are acceptable as equivalent, compared to Synacthen. The 
two ACTH preparations can be considered to generate bioequivalent cortisol concentrations in healthy dogs. 
Further equivalence testing in ill dogs is needed to allow results to be generalised to the wider canine population. 
This current study was limited to healthy dogs but inadvertently included 2 dogs that had markedly abnormal 
cortisol concentrations after ACTH stimulation. Although not being included in the statistical analysis, the 
respective cortisol concentrations after Bova and Synacthen administration for each of the 2 dogs were very 
similar.  
Dog 11 showed minimal increase in cortisol concentrations (16.4 nmol/L after Synacthen and 15.1 nmol/L after 
Bova ACTH, RI 180-380 nmol/L) and was diagnosed with hypoadrenocorticism. He was successfully treated with 
cortisone acetate 12.5 mg (0.56 mg/kg) once a day starting on 18/8/18. Dog 9 showed excessive adrenal 
stimulation suggestive of hyperadrenocorticism (cortisol concentration: 473.2 nmol/L after Synacthen and 487.7 
nmol/L after Bova ACTH). However, Dog 9 had normal cortisol suppression after low-dose dexamethasone 
administration, which suggested normal HPA function and that the ACTH stimulation was a false positive result. 
Reported specificities of ACTH stimulation for diagnosing hyperadrenocorticism vary from 0.59 (95% CI 0.454-
0.707),(49) 0.86,(27) to 0.91.(34) False positive results have been reported in association with stress from non-
adrenal illnesses, however no plausible illness could be identified in Dog 9 based on the history or 
clinicopathologic findings.(27, 198) The cause of the high cortisol concentration in Dog 9 is unknown. More 
importantly, identical conclusions were reached based on the cortisol concentrations after both ACTH 
preparations. Thus, results from Dog 11 and 9 suggest that ACTH equivalence is present even when cortisol 
concentrations are outside of RI, in line with the agreement found in the 18 healthy dogs.  
In addition, another 4 dogs had at least one cortisol concentration outside of the RI after ACTH stimulation. Two 
dogs had concentrations slightly below the RI (Dog 7 and 16) and 2 dogs had concentrations slightly above the 
RI (Dog 10 and 20). In a clinical setting, these 4 dogs would still be considered to have a normal HPA axis, which 
is supported by their history, haematology, biochemistry and urinalysis results. A slight deviation outside the 
laboratory RI can occur in healthy dogs and the laboratory RI is not intended to be used as an absolute cut-off 
value to discriminate between healthy and diseased dogs. It is also possible that the laboratory RI was 
excessively narrow for the population of dogs under study.  
Two dogs had suboptimal stimulation after both preparations of ACTH (Dog 7 cortisol concentration: 150.1 
nmol/L after Synacthen and 170.2 nmol/L after Bova ACTH; Dog 16 cortisol concentration: 125.1 nmol/L after 
Synacthen and 114.6 nmol/L after Bova ACTH; RI 180-380 nmol/L). Suboptimal stimulation less than the lower 
RI but above the diagnostic cut-off for hypoadrenocorticism should prompt further investigation such as ruling out 
a deviation from test protocol, inadequate potency of the ACTH used, or causes of adrenal suppression such as 
treatment with glucocorticoids, mitotane, trilostane or ketoconazole.(3) A deviation from test protocol or 
inadequate ACTH potency were unlikely given the repeatable findings from both days of testing and using 2 
different preparations of ACTH. Moreover, the same batch numbers of Synacthen and Bova were used for other 
dogs in the study with no results outside the RI. Prior administration of exogenous glucocorticoids and other 
medications had been excluded as part of the study inclusion criteria and compliance was rechecked after 
receiving the results. Individual variation or early hypoadrenocorticism are the two remaining possibilities for 
suboptimal ACTH stimulation and determination of the latter would require follow up ACTH stimulations, which 
was beyond the scope of this study.     
The phenomenon of suboptimal ACTH stimulation had been examined by a retrospective study in dogs, which 
provided follow-up information on dogs with mildly low cortisol concentrations.(199) The inclusion criteria 
consisted of a cortisol concentration after ACTH stimulation that was above the cut-off for a diagnosis of 
hypoadrenocorticism but below the lower reference limit. Specifically, cases were reviewed if cortisol 
concentrations were above 55.2 nmol/L and below 220.8 nmol/L between January 2004 to July 2010, and below 
276.0 nmol/L between July 2010 to June 2014 (the slight discrepancy was due to a change of laboratory in 
2010). Nine dogs were found to fit the inclusion criteria, with cortisol concentrations ranging from 94-223 nmol/L 
after ACTH stimulation. Of the 7 dogs that had follow-up, 2 dogs did not require long-term glucocorticoid 
treatment, 4 dogs were diagnosed with inflammatory bowel disease (likely causing the gastrointestinal signs) and 
1 dog remained ill despite glucocorticoid administration.(199) Based on this small number of dogs, a suboptimal 
stimulation result had poor positive predictive value for a diagnosis of hypoadrenocorticism during the follow-up 
period (ranging from 10-77 months). 
Three cortisol concentrations from 2 dogs were slightly above the reference limit after ACTH stimulation. Dog 10 
had a cortisol concentration of 383 nmol/L after Synacthen and Dog 20 had a cortisol concentration of 387.3 
nmol/L after Bova and 388.0 nmol/L after Synacthen (RI 180-380 nmol/L). The lack of compatible clinical signs 
made a diagnosis of hyperadrenocorticism very unlikely. A physiological cause, such as stress, was more likely 
to have contributed to increased t=1 cortisol concentrations. Stress-related cortisol production is further 
supported by higher t=0 cortisol concentrations in Dog 10 and 20 compared to other dogs in the study.  
Equivalency studies must always define what constitutes equivalence. The limits of agreement used in this study 
were based on clinical judgement and previous equivalency studies of cortisol concentrations in dogs. Two 
previous studies in dogs have investigated equivalence of cortisol concentrations after different ACTH doses and 
wash-out intervals between tests.(73, 200) Both of these studies defined equivalence to be present if the 90% CI 
of the mean cortisol ratio was within 0.80-1.25. In contrast, the current study chose a higher CI of 95% when 
assessing the cortisol ratio after Bova ACTH and Synacthen. Despite this slight difference in CI, the data from the 
two previous studies suggest that cortisol concentrations after ACTH administration fall within a narrow range 
when performed repeatedly and that a ratio range of 0.8-1.25 would be a reasonable criterion for equivalence. 
The range is also used by The Food and Drug Administration as a generic ratio range for pharmacokinetic 
studies of bioequivalence between drugs with a wide safety margin.(95) 
One potential cause for variability is the carry-over effect of the first ACTH stimulation test on the results of the 
second. Thus, an adequate wash-out interval between the first and second ACTH stimulation test was required 
and a cross over design was used to help reveal any potential bias. A 24-hour testing interval was chosen for this 
study based on research by Lathan and others (2008), who compared t=1 cortisol concentrations after ACTH 
stimulation between a 24-hour versus 2-week wash-out interval, as well as two different doses (5 µg/kg versus 
250 µg/dog) of Synacthen.(200) Eight healthy dogs received two different doses of Synacthen over 2 days, and 
then had two further doses of Synacthen over 2 days after a 2-week interval. The 90% CI of the ratio of mean 
cortisol concentrations after ACTH stimulation between the first and second week was 105.6-113.1%, which was 
within their pre-determined equivalence range of 80-125%. The 90% CI of the ratio between cortisol 
concentrations after ACTH stimulation performed 24 hours apart was 86.7-101.2%. Their results suggest that 
cortisol concentrations were equivalent after ACTH stimulation performed 24 hours versus 2 weeks apart, as well 
as after 5 µg/kg versus 250 µg/dog of Synacthen. Other studies have investigated results of sequential ACTH 
stimulation tests at variable time intervals, ranging from an interval of 3 hours,(73) 1 day,(98) 3-4 days,(72) 1 
week,(201) 1-2 weeks,(80), 2 weeks,(71) and 4-8 weeks.(56) These studies did not provide evidence or 
justification for these wash-out intervals. The benefit of having a shorter wash-out interval included decreasing 
the risk of new illness, stress or an event occurring between the first and second ACTH stimulation test, which 
could affect adrenal cortisol secretion. 
The basal (t=0) cortisol concentrations of the 18 healthy dogs were not significantly different between the first and 
second days of testing. The return to the Day 1 basal cortisol concentration by Day 2 supports the adequacy of our 
washout period and our assumption that the second ACTH stimulation was not affected by the first. The two 
exceptions were Dog 10 and Dog 20, both of which had much higher basal cortisol concentrations on Day 1 of 
testing (Synacthen for both dogs) compared to Day 2. Both dogs displayed signs of anxiety and stress on Day 1 
but appeared less stressed and more acclimatised to the handling and venepuncture on Day 2. Environmental 
stress was considered the most  likely cause of the difference in t=0 cortisol concentrations between the test days 
for these 2 dogs. 
Five different batches of Bova ACTH were used in the study and the overall good agreement of t=1 cortisol 
concentrations suggest there is minimal inter-batch variation. Based on visual inspection of the Bland-Altman 
graph, there was no apparent bias from different ACTH batches, the date of testing, or the order of ACTH testing. 
The 95% CI of the limits of agreement of Bland-Altman analysis provided further support for cortisol equivalence.  
Other factors that may introduce variance into the study were considered, including laboratory variance and  
effects of handling. A chemiluminescent assay (ADVIA Centaur® Cortisol assay, Bayer Diagnostics, Leverkusen, 
Germany; acquired by Siemens, München, Germany in 2007)(202) was used to measure the serum cortisol 
concentrations. Based on the intra-assay and inter-assay CV, the ADVIA Centaur cortisol assay has good 
precision, which is important to help minimise variation in an equivalence study. In people, a study has found 
acceptable performance by the ADVIA Centaur cortisol assay,(203) however, a similar study in dogs has not 
been published. The laboratory Vetnostics had internally validated the ADVIA Centaur cortisol assay against the 
radioimmunoassay in the past, but the original data is unavailable.(197) Potential disagreement between cortisol 
concentrations from different assays is not a major concern for this current study, as the same assay was used 
for all samples and each dog acted as its own control.  
Another potential cause of variation can occur during sample handling, including the different storage durations 
for the serum samples. Reimer and others (1982) found that cortisol concentrations did not change significantly 
after being stored for 8 days at -20oC.(87) Whilst an experimental study has not directly examined the effect of 
prolonged storage at -80oC on cortisol concentrations, the effects of storage on the current study were assumed 
to be minimal. As each dog was tested on two consecutive days, the paired t=1 serum samples under 
comparison only had a 24-hour difference in storage duration. Any potential degradation of cortisol 
concentrations from the storage process would be expected to have an equal effect on both paired samples. 
Despite the non-inferiority of the Bova ACTH preparation, a major practical disadvantage is the 3-day beyond-
use-date, which was instituted in the midst of this current study. The ACTH stimulation results from the 6 dogs 
that were tested prior to 1st February (using the 3-month expiry) would suggest that the Bova ACTH remained 
biologically active past the 3-day beyond-use-date. The change in beyond-use-date was not accompanied by any 
changes in the formulation. It should be noted that this study did not examine sterility or other risks of 
compounded preparations, which are separate considerations when following the beyond-use-date and product 
safety guidelines. Another practical disadvantage of Bova ACTH is the lack of information relating to long-term 
stability when stored frozen. By comparison, Cortrosyn (a commercial ACTH similar to Synacthen) is stable at -
20oC for up to 6 months.(204) If further studies can demonstrate that freezing does not affect the activity of Bova 
ACTH, this may allow increased flexibility when using the preparation. 
4.5 Conclusion 
The availability of Bova ACTH (tetracosactide) increases the options for Australian veterinarians investigating 
canine hypoadrenocorticism, hyperadrenocorticism, iatrogenic hyperadrenocorticism, or when monitoring medical 
treatment of hyperadrenocorticism using mitotane or trilostane. Bova ACTH produced equivalent cortisol 
concentrations compared to the reference Synacthen in healthy dogs. The 95% CI of the ratio between cortisol 
concentration after Bova ACTH and Synacthen was contained within the pre-determined equivalence range of 
0.80-1.25. The use of Bova ACTH has not been fully studied in dogs with adrenal illness, but based on the data 
in healthy dogs, it is an option for ACTH stimulation tests as a substitute for Synacthen when availability or cost 
of the latter are an issue. Two dogs that had significantly abnormal cortisol concentrations after ACTH stimulation 
were excluded from statistical analysis but had similar, corresponding cortisol concentrations after both ACTH 
preparations. Unfortunately, the new 3-day beyond-use-date of Bova ACTH decreases the practicality and 
flexibility for veterinary hospitals when using this formulation.  
5. Relationship between cortisol concentration and subject 
variables 
The aim of the third phase of this thesis was to explore potential effects of subject variables on variations in 
cortisol concentration after ACTH stimulation. Any association of subject variables with the variation on cortisol 
concentration might direct future consideration of stratifying expected changes in the HPA axis according to the 
presence of these variables. 
5.1 Methodology 
The serum cortisol concentrations from the 18 healthy dogs after Synacthen stimulation were used for analysis.  
Multiple linear regression was used to determine the best subset of variables that explained the variance in t=1 
cortisol concentration. Variables entered into the model included basal (t=0) cortisol concentration, sex, neuter 
status, age, body condition score, sodium: potassium ratio, haematocrit, neutrophil count, eosinophil count, 
lymphocyte count, and presence or absence of a stress leukogram.  
The best subset was selected based on the R2 (highest) for single variables, adjusted R2 (highest) for >1 variable, 
and Mallow’s p (Cp’ lowest). Based on results of this analysis, univariate comparison of serum cortisol 
concentration for the single-most explanatory variable was performed using a t-test, with a Pooled or 
Satterthwaite p ≤0.05 considered significant, depending on equality of variances, respectively. SAS v 9.4 (SAS 
Institute, Cary, North Carolina, USA) was used for the analysis.  
  
5.2 Results 
The best single variable was neutered status, with neutering explaining 48% of the variance in t=1 cortisol 
concentration. The t=1 cortisol for the 4 entire dogs (3 female and 1 male) was lower (mean 176.6 nmol/L, SD 
46.6, range 125.1-222.2) compared to the 14 neutered dogs (5 females and 9 males) (mean 293.2 nmol/L, SD 
55.6, range 201.8-388). This difference was statistically significant (p=0.0016, t test, equal variance). Note that 
there was no significant difference in basal cortisol between the entire dogs (mean 53.1 nmol/L, SD 77.1, range 
13.7-315.2) or neutered dogs (mean 20.2 nmol/L, SD 5.7, range 14.0-27.4, p=0.1376, t test, unequal variance).  
Inclusion of t=0 cortisol concentration, in addition to neuter status, improved the explanation to 55% and the 
addition of lymphocyte count improved the explanation to 57% (Table 22). As a single variable, t=0 cortisol 
concentration only accounted for 24% of the t=1 cortisol variation. The remaining subject variables, when 
examined individually, had poor association with cortisol concentration. The full table of variables for multiple 






C(p) Variables in Model 
1 0.4750 0.4422 -2.1678 sex_cat* 
1 0.2448 0.1976 3.0199 cort_0 
1 0.0731 0.0152 6.8891 na_k 
1 0.0687 0.0105 6.9888 lymph 
1 0.0564 -.0026 7.2664 sex_mf 
1 0.0249 -.0361 7.9773 stress 
1 0.0119 -.0498 8.2687 neut 
1 0.0064 -.0557 8.3925 bcs 
1 0.0022 -.0602 8.4886 age 
1 0.0016 -.0608 8.5016 eos 
1 0.0000 -.0625 8.5374 ht 
2 0.6060 0.5534 -3.1192 cort_0 sex_cat** 
2 0.5455 0.4849 -1.7576 sex_cat ht 
2 0.5118 0.4467 -0.9979 sex_cat na_k 
2 0.4985 0.4316 -0.6975 sex_cat neut 
2 0.4942 0.4267 -0.5999 sex_cat lymph 
2 0.4828 0.4138 -0.3437 sex_cat bcs 
2 0.4767 0.4069 -0.2060 sex_cat age 
2 0.4757 0.4058 -0.1831 sex_cat stress 
2 0.4756 0.4057 -0.1817 sex_cat eos 
2 0.4751 0.4051 -0.1708 sex_mf sex_cat 
2 0.3736 0.2901 2.1170 cort_0 stress 






C(p) Variables in Model 
3 0.6482 0.5728 -2.0716 cort_0 sex_cat lymph*** 
3 0.6431 0.5666 -1.9559 cort_0 sex_cat age 
3 0.6381 0.5605 -1.8427 cort_0 sex_cat na_k 
3 0.6275 0.5477 -1.6055 cort_0 sex_cat stress 
3 0.6207 0.5394 -1.4517 cort_0 sex_cat bcs 
3 0.6151 0.5326 -1.3247 cort_0 sex_cat eos 
3 0.6120 0.5289 -1.2556 cort_0 sex_cat neut 
3 0.6095 0.5258 -1.1992 sex_mf cort_0 sex_cat 
3 0.6077 0.5236 -1.1580 cort_0 sex_cat ht 
3 0.5942 0.5072 -0.8544 sex_cat ht lymph 
Table 23 Multivariable regression analysis of variance in cortisol associated with 13 categories. Sex_cat, neuter 
status; cort_0, basal cortisol; na_k, sodium: potassium ratio; lymph, lymphocyte count; sex_mf, sex; stress, stress 
leukogram (present or absent); neut, neutrophil count; bcs, body condition score; eos, eosinophil count; ht, 
haematocrit; * single best explanatory variable; ** two best explanatory variables; *** three best explanatory 




The results of multiple linear regression suggest that subject variables are associated with serum cortisol 
concentration after ACTH stimulation. Neuter status was the single-most explanatory variable associated with 
cortisol concentration, with the possibility that neutered dogs have higher cortisol concentrations. The total 
number of dogs, especially the number of entire dogs, was small, and thus the findings are preliminary.  
The current results differed slightly to a previous study of 97 dogs, which reported that entire male dogs had 
lower serum cortisol concentrations after ACTH stimulation compared to neutered male, entire female and 
neutered female dogs.(137) In the current study, only 1 out of 4 entire dogs was male and it is unclear whether 
the effect of neutering differs between females and males. There were too few dogs to stratify between female 
entire and male entire dogs for comparison.  
Three of the intact dogs were French bulldogs and potential breed-related differences affecting cortisol 
concentrations cannot be excluded. One previous study has examined potential breed-related effects on basal 
cortisol concentrations.(205) Among the 9 dog breeds examined, Finnish Lapphunds had the highest median 
plasma cortisol concentration (85 nmol/L) and Boxers had the lowest (31.5 nmol/L); no French bulldogs 
participated in the study. A limitation of the study was that all the Finnish Lapphunds and Boxers were intact 
males and thus effects of sex and neuter status could not be assessed. Another limitation was that all the Finnish 
Lapphunds were examined in Finland, whilst all the Boxers were examined in Sweden.  
Sex alone, was a poor explanatory variable, only accounting for 5% of the variance in cortisol concentration. This 
is in agreement with a previous study of 29 female and 29 male beagles (unknown neuter status), that did not 
have significantly different cortisol concentrations after ACTH stimulation.(121) In contrast, a small study found 
that females had significantly higher plasma cortisol concentration 1-2 hours after ACTH stimulation, when 
comparing 4 female cocker spaniels with 3 male cocker spaniels.(115) It remains unclear whether sex is an 
significant variable affecting cortisol concentrations until a larger study including different breeds and larger 
number of dogs can examine this issue.  
The association of subject variables on cortisol concentration might suggest that different RI is required for neuter 
status and sex. Sex and neuter-specific RI were used as part of a previous study examining Scottish terriers and 
hyperadrenocorticism.(206) Zimmerman and others generated RI from data obtained from healthy dogs, which 
resulted in a lower cortisol concentration cut-off for the diagnosis of hyperadrenocorticism in male entire dogs 
compared to male neutered dogs. Both entire and neutered male dogs had lower cortisol cut-offs than entire and 
neutered female dogs. The population of dogs in the current study is too small to generate specific RI for male 
entire, male neutered, female entire and female neutered groups. Further research into sex and neuter specific 
RI is indicated, followed by comparison of test sensitivity and specificity to determine potential benefits (or lack 
thereof) of the specific RI. 
Haematologic and biochemical abnormalities are more typically identified in dogs with HPA dysfunction. For 
example, hypoadrenocorticism is associated with a lack of a stress leukogram, hyponatraemia, and 
hyperkalaemia.(18) As only the 18 healthy dogs were included in multiple linear regression analysis, normal 
electrolyte and leukograms were expected and there was less likely to be a detectable association between 
cortisol and laboratory parameters.   
In conclusion, multivariable regression analysis suggests neuter status explains a substantial proportion of the 
variance in cortisol concentrations after ACTH stimulation. Further investigation is required to determine if the 
degree of variability is repeatable and whether this should affect RI for neutered versus entire dogs. 
 
6. General discussion and conclusion 
The process of verifying a compounded pharmaceutical product generates an equivalent response is important to 
ensure there is confidence in assessing its effect compared to an established product. This thesis describes the 
completion of an experimental study to investigate the equivalence between the cortisol response to 
compounded Bova ACTH and the reference Synacthen in healthy dogs. The cortisol concentrations 1 hour after 
both ACTH preparations were deemed equivalent, as the 95% CI of the ratio of the mean cortisol concentration 
(Bova ACTH/Synacthen) was 0.98-1.04, within the pre-determined equivalence range of 0.8-1.25. Bland-Altman 
and Passing-Bablok analyses also supported equivalency between Bova ACTH and Synacthen without evidence 
of bias.  
This study only included healthy dogs and the statistical analysis was limited to ACTH stimulation tests that were 
considered normal. A further step in evaluating Bova ACTH would be to conduct the same experiment in dogs 
with hypoadrenocorticism and dogs with hyperadrenocorticism, to confirm that equivalency in the response is 
maintained at very low and very high cortisol concentrations. This study inadvertently enrolled 1 dog with 
hypoadrenocorticism and 1 dog with markedly elevated post-ACTH serum cortisol concentration. The results 
from these 2 dogs suggest that a similar study focusing on ill dogs may also support equivalency in the cortisol 
response. 
The results of this study afford confidence for veterinarians in choosing the Bova ACTH as an alternative source 
of synthetic ACTH, which is particularly helpful during shortages of the standard preparation, Synacthen. A 
reliable and readily available ACTH is essential for the diagnosis and management of pituitary and adrenal 
diseases in dogs. Shortages of Synacthen can have serious clinical impacts on the health of canine patients. In 
addition, owner finances affect treatment decisions of veterinary patients and potential cost savings from 
compounded ACTH can be advantageous for patients and owners. The main limitation of Bova ACTH is the 3 
day beyond-use-date which complicates the logistics of storage in veterinary practice. 
As part of the main study, RI were established for 17 biochemistry analytes using two different methodologies: 
transference and de novo generation. The RI were then used in the equivalence study to screen healthy dogs 
prior to enrolment. 
Lastly, the association of subject characteristics on ACTH stimulation test results was analysed using data 
sourced from the equivalency experiment. The most interesting finding was the association of neuter status with 
cortisol concentration after ACTH stimulation, and the corresponding finding of a significantly lower cortisol 
concentration after ACTH stimulation in neutered dogs compared to entire dogs. Future research is indicated to 
explore this result. Different RI for blood cortisol concentration may be appropriate for dogs that are neutered 
versus entire. More targeted RI could then increase the sensitivity and specificity of testing for diseases such as 
hyperadrenocorticism. 
In conclusion, veterinary practitioners can expect that 5 µg/kg Bova ACTH IV will produce equivalent serum 
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Appendix 2 Multiple linear regression analysis 
Dependent Variable: cort_1   
R-Square Selection Method 
Number of Observations Read 18 





C(p) Variables in Model 
1 0.4750 0.4422 -2.1678 sex_cat 
1 0.2448 0.1976 3.0199 cort_0 
1 0.0731 0.0152 6.8891 na_k 
1 0.0687 0.0105 6.9888 lymph 
1 0.0564 -.0026 7.2664 sex_mf 
1 0.0249 -.0361 7.9773 stress 
1 0.0119 -.0498 8.2687 neut 
1 0.0064 -.0557 8.3925 bcs 
1 0.0022 -.0602 8.4886 age 
1 0.0016 -.0608 8.5016 eos 
1 0.0000 -.0625 8.5374 ht 
2 0.6060 0.5534 -3.1192 cort_0 sex_cat 
2 0.5455 0.4849 -1.7576 sex_cat ht 
2 0.5118 0.4467 -0.9979 sex_cat na_k 
2 0.4985 0.4316 -0.6975 sex_cat neut 
2 0.4942 0.4267 -0.5999 sex_cat lymph 
2 0.4828 0.4138 -0.3437 sex_cat bcs 
2 0.4767 0.4069 -0.2060 sex_cat age 
2 0.4757 0.4058 -0.1831 sex_cat stress 
2 0.4756 0.4057 -0.1817 sex_cat eos 
2 0.4751 0.4051 -0.1708 sex_mf sex_cat 
2 0.3736 0.2901 2.1170 cort_0 stress 
3 0.6500 0.5750 -2.1128 sex_cat ht na_k 
3 0.6482 0.5728 -2.0716 cort_0 sex_cat lymph 
3 0.6431 0.5666 -1.9559 cort_0 sex_cat age 
3 0.6381 0.5605 -1.8427 cort_0 sex_cat na_k 
3 0.6275 0.5477 -1.6055 cort_0 sex_cat stress 
3 0.6207 0.5394 -1.4517 cort_0 sex_cat bcs 
3 0.6151 0.5326 -1.3247 cort_0 sex_cat eos 
3 0.6120 0.5289 -1.2556 cort_0 sex_cat neut 
3 0.6095 0.5258 -1.1992 sex_mf cort_0 sex_cat 





C(p) Variables in Model 
3 0.5942 0.5072 -0.8544 sex_cat ht lymph 
4 0.6819 0.5841 -0.8314 sex_cat ht lymph na_k 
4 0.6753 0.5753 -0.6812 cort_0 sex_cat age lymph 
4 0.6671 0.5647 -0.4970 cort_0 sex_cat age na_k 
4 0.6662 0.5634 -0.4759 cort_0 sex_cat lymph na_k 
4 0.6660 0.5632 -0.4727 cort_0 sex_cat ht na_k 
4 0.6644 0.5611 -0.4360 cort_0 sex_cat eos na_k 
4 0.6619 0.5578 -0.3791 sex_cat ht eos na_k 
4 0.6610 0.5567 -0.3602 sex_cat ht neut na_k 
4 0.6608 0.5564 -0.3543 cort_0 sex_cat bcs na_k 
4 0.6594 0.5546 -0.3233 sex_cat stress ht na_k 
4 0.6590 0.5541 -0.3147 cort_0 sex_cat bcs lymph 
5 0.7068 0.5846 0.6084 cort_0 sex_cat bcs eos na_k 
5 0.7007 0.5760 0.7452 cort_0 sex_cat ht lymph na_k 
5 0.6981 0.5723 0.8048 cort_0 sex_cat age neut lymph 
5 0.6908 0.5620 0.9676 sex_mf sex_cat ht lymph na_k 
5 0.6891 0.5596 1.0061 cort_0 sex_cat age lymph na_k 
5 0.6867 0.5562 1.0604 cort_0 sex_cat bcs ht na_k 
5 0.6859 0.5550 1.0790 cort_0 sex_cat ht eos na_k 
5 0.6846 0.5532 1.1081 sex_cat bcs ht lymph na_k 
5 0.6841 0.5525 1.1188 cort_0 sex_cat stress ht na_k 
5 0.6831 0.5510 1.1427 cort_0 sex_cat bcs lymph na_k 
5 0.6826 0.5504 1.1529 sex_cat stress ht lymph na_k 
6 0.7236 0.5729 2.2283 cort_0 sex_cat bcs ht eos na_k 
6 0.7151 0.5597 2.4208 cort_0 sex_cat bcs ht lymph na_k 
6 0.7090 0.5502 2.5587 cort_0 sex_cat bcs stress eos na_k 
6 0.7086 0.5496 2.5676 cort_0 sex_cat bcs neut eos na_k 
6 0.7075 0.5480 2.5921 cort_0 sex_cat age bcs eos na_k 
6 0.7069 0.5470 2.6063 sex_mf cort_0 sex_cat bcs eos na_k 
6 0.7068 0.5469 2.6081 cort_0 sex_cat bcs eos lymph na_k 
6 0.7062 0.5460 2.6214 cort_0 sex_cat age ht lymph na_k 
6 0.7042 0.5429 2.6665 cort_0 sex_cat ht neut lymph na_k 
6 0.7033 0.5415 2.6862 cort_0 sex_cat age neut lymph na_k 
6 0.7022 0.5398 2.7118 sex_mf cort_0 sex_cat ht lymph na_k 
7 0.7285 0.5385 4.1189 sex_mf cort_0 sex_cat bcs ht eos na_k 
7 0.7252 0.5328 4.1934 cort_0 sex_cat bcs ht eos lymph na_k 





C(p) Variables in Model 
7 0.7242 0.5312 4.2151 cort_0 sex_cat bcs ht neut eos na_k 
7 0.7238 0.5304 4.2256 cort_0 sex_cat bcs stress ht eos na_k 
7 0.7194 0.5229 4.3248 sex_mf cort_0 sex_cat bcs ht lymph na_k 
7 0.7166 0.5182 4.3880 cort_0 sex_cat age ht neut lymph na_k 
7 0.7164 0.5179 4.3910 cort_0 sex_cat age bcs ht lymph na_k 
7 0.7154 0.5162 4.4139 cort_0 sex_cat bcs ht neut lymph na_k 
7 0.7154 0.5161 4.4150 cort_0 sex_cat bcs stress ht lymph na_k 
7 0.7115 0.5096 4.5019 cort_0 sex_cat bcs stress neut eos na_k 
8 0.7313 0.4925 6.0556 sex_mf cort_0 sex_cat age bcs ht eos na_k 
8 0.7300 0.4900 6.0853 sex_mf cort_0 sex_cat bcs ht eos lymph na_k 
8 0.7290 0.4882 6.1070 sex_mf cort_0 sex_cat bcs ht neut eos na_k 
8 0.7285 0.4872 6.1186 sex_mf cort_0 sex_cat bcs stress ht eos na_k 
8 0.7275 0.4853 6.1414 cort_0 sex_cat bcs ht neut eos lymph na_k 
8 0.7258 0.4821 6.1798 cort_0 sex_cat bcs stress ht eos lymph na_k 
8 0.7257 0.4818 6.1824 cort_0 sex_cat age bcs ht eos lymph na_k 
8 0.7252 0.4808 6.1943 cort_0 sex_cat age bcs stress ht eos na_k 
8 0.7250 0.4805 6.1980 cort_0 sex_cat age bcs ht neut eos na_k 
8 0.7245 0.4796 6.2092 cort_0 sex_cat bcs stress ht neut eos na_k 
8 0.7199 0.4710 6.3117 sex_mf cort_0 sex_cat bcs stress ht lymph na_k 
9 0.7321 0.4308 8.0371 sex_mf cort_0 sex_cat bcs ht neut eos lymph na_k 
9 0.7318 0.4300 8.0453 sex_mf cort_0 sex_cat age bcs ht eos lymph na_k 
9 0.7315 0.4295 8.0511 sex_mf cort_0 sex_cat age bcs stress ht eos na_k 
9 0.7313 0.4291 8.0551 sex_mf cort_0 sex_cat age bcs ht neut eos na_k 
9 0.7303 0.4268 8.0791 sex_mf cort_0 sex_cat bcs stress ht eos lymph na_k 
9 0.7299 0.4260 8.0874 cort_0 sex_cat bcs stress ht neut eos lymph na_k 
9 0.7291 0.4243 8.1055 sex_mf cort_0 sex_cat bcs stress ht neut eos na_k 
9 0.7276 0.4211 8.1399 cort_0 sex_cat age bcs ht neut eos lymph na_k 
9 0.7264 0.4187 8.1655 cort_0 sex_cat age bcs stress ht eos lymph na_k 
9 0.7254 0.4165 8.1883 cort_0 sex_cat age bcs stress ht neut eos na_k 
9 0.7215 0.4083 8.2758 sex_mf cort_0 sex_cat age bcs ht neut lymph na_k 
10 0.7337 0.3533 10.0014 sex_mf cort_0 sex_cat bcs stress ht neut eos lymph na_k 
10 0.7324 0.3502 10.0305 sex_mf cort_0 sex_cat age bcs ht neut eos lymph na_k 
10 0.7322 0.3496 10.0358 sex_mf cort_0 sex_cat age bcs stress ht eos lymph na_k 
10 0.7316 0.3481 10.0501 sex_mf cort_0 sex_cat age bcs stress ht neut eos na_k 
10 0.7302 0.3447 10.0813 cort_0 sex_cat age bcs stress ht neut eos lymph na_k 
10 0.7215 0.3238 10.2757 sex_mf cort_0 sex_cat age bcs stress ht neut lymph na_k 





C(p) Variables in Model 
10 0.7195 0.3188 10.3218 sex_mf cort_0 sex_cat age bcs stress neut eos lymph na_k 
10 0.7110 0.2982 10.5128 sex_mf sex_cat age bcs stress ht neut eos lymph na_k 
10 0.7038 0.2806 10.6758 sex_mf cort_0 sex_cat age bcs stress ht neut eos lymph 
10 0.5451 -.1047 14.2521 sex_mf cort_0 age bcs stress ht neut eos lymph na_k 
11 0.7338 0.2457 12.0000 sex_mf cort_0 sex_cat age bcs stress ht neut eos lymph na_k 
Sex_cat, neuter status; cort_0, basal cortisol; na_k, sodium: potassium ratio; lymph, lymphocyte count; sex_mf, 
sex; stress, stress leukogram (present or absent); neut, neutrophil count; bcs, body condition score; eos, 
eosinophil count; ht, haematocrit 
